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ABSTRACT 
Introduction: Athrixia phylicoides is an aromatic, indigenous shrub with high antioxidant 
content and numerous indigenous medicinal properties inferred by ingestion of an herbal 
brew of the plant. Commercialization of “bush tea” (derived from A. phylicoides) holds 
economic and developmental potential for indigenous communities provided the safety 
and efficacy of the herbal tea is established. Recently A. phylicoides has been shown by 
McGaw et al. (2007) to have similar antioxidant activity to Rooibos tea, and a unique, new 
flavonol (i.e. a polyphenolic antioxidant plant metabolite) 5-hydroxy-6,7,8,3′,4′,5′-
hexamethoxyflavon-3-ol, unique to A. phylicoides, was isolated by Mashimbye et al. in 
2006. With changes in the socio-economic climate and a new trend in merging Western 
lifestyle with traditional practices, new interest has been shown in herbal/natural remedies. 
Study Aim: The aim of this study was to firstly, determine the in vitro effect of A. 
phylicoides aqueous extract on glucose metabolism in cell lines that mimic the three key 
organs implicated in glucose homeostasis. Secondly, the study aimed to determine the 
potential ex vivo antioxidant and anti-inflammatory effect of the extract in pancreatic β-cells 
and peripheral mononuclear cells respectively. 
Methods: Leaves and fine twigs of A. phylicoides were processed into an aqueous 
extract. C2C12, Chang and 3T3-L1 cells were cultured under standard conditions and 
acutely exposed to increasing concentrations of extract and water vehicle, as well as 1 μM 
insulin and metformin as positive controls. Glucose uptake from 8 mM glucose culture 
media was determined using a fluorimetric oxidase method. Radioactive 14C-glucose 
oxidation to 14CO2 and determination of glycogen content of cells were used to assess the 
fate of intracellular glucose. RT-PCR was used to assess the extract effect on insulin-
signalling gene expression. The antioxidative effect of A. phylicoides extract in pancreatic 
β-cells isolated from Wistar rats was determined by measuring nitric oxide (NO) production 
in response to hyperglycemic conditions. NO was labelled with diaminofluorocein diacetate 
and fluorescence was measured using flow cytometry. Insulin secretion of pancreatic β-
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cells was measured using radio-immuno assay. The anti-oxidative effect of the extract in 
lipopolysaccharide-stimulated peripheral mononuclear cells isolated from Wistar rats was 
determined by measuring the production of TNF-α using an ELISA kit. 
Results: C2C12 myocytes showed maximal increased glucose uptake at the 0.05 μg/μl 
extract concentration (228.3% ± 66.2, p<0.001). In Chang cells, A. phylicoides extract 
maximally increased the amount of glucose taken up at the 0.05 μg/μl concentration 
(134.5% ± 2.5, p<0.05). In 3T3-L1 cells, the extract maximally increased the amount of 
glucose taken up at the 0.025 μg/μl concentration (143.5% ± 10.3, p<0.001). An extract-
induced increase in insulin receptor and glucose transporter four expression was seen in 
C2C12 myocytes. The oxidation of 14C-glucose to 14CO2 by C2C12 myocytes was 
maximally increased following acute exposure to the extract at 0.1 μg/μl (2919.3 
fmol/1x10^6 cells ± 428, p<0.01). The oxidation of 14C-glucose to 14CO2 by Chang cells 
was maximally increased following acute exposure to extract at 0.1 μg/μl (4476.7 
fmol/1x10^6 cells ± 1620, p<0.05); as seen in the C2C12 cells. A. phylicoides extract 
increased glycogen storage at all three concentrations tested in Chang cells, but 
maximally at the 0.025 μg/μl concentration (13.6 μg/1x10^6 cells ± 0.7, p<0.05). A. 
phylicoides extract did not have any measurable effect on the oxidative status of β-cells or 
the anti-inflammatory status of peripheral mononuclear cells. The extract did show an 
increase in first phase insulin secretion of β-cells in hyperglycemic conditions, although it 
was not significant. 
  
Conclusion: Athrixia phylicoides aqueous extract stimulates in vitro glucose uptake and 
metabolism in an insulin-mimetic manner, suggesting that this extract could potentially be 
beneficial to type two diabetics as an adjunct therapy. 
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ABSTRAK 
Inleiding: Athrixia phylicoides is „n aromatiese, inheemse struik met „n hoë antioksidant 
inhoud. Vele tradisionele medisinale eienskappe is gekoppel aan die ingestie van „n kruie 
brousel van die plant, wat ook bekend as “bostee” is. Kommersialisering van “bostee” hou 
ekonomiese en ontwikkelings potensiaal in vir inheemse gemeenskappe mits die veiligheid 
en effektiwiteit van die kruietee bevestig kan word. McGaw et al. (2007) het onlangs 
bevind dat A. phylicoides se antioksidant aktiwiteit vergelykbaar is met die van rooibostee. 
„n Unieke  nuwe flavonol („n polifenoliese antioksidant plant metaboliet) 5-hydroksie-
6,7,8,3′,4′,5′-hexamethoksieflavon-3-ol, eie aan A. phylicoides, is deur Mashimbye et al. in 
2006 geïsoleer. Met veranderings in die sosio-ekonomiese klimaat en „n nuwe tendens om 
die westerse lewenstyl met trandisionele gebruike aantevul word nuwe belangstelling in 
kruie/natuurlike rate ondervind. 
Studie Doelwitte: Die doelwitte van hierdie studie was eerstens om die in vitro effek van 
A. phylicoides waterekstrak op die glukosemetabolisme van drie sellyne wat die sleutel 
organe naboots wat glukosehomeostase beheer, te bepaal. Tweedens, is die potensiële 
ex vivo antioksidant en anti-inflammatoriese effek van die ekstrak op pankreatiese β-selle 
en perifere mononuklêere-selle onderskeidelik ondersoek. 
Metodes: n Waterige ekstrak is van die blare en fyn takkies van A. phylicoides berei. 
C2C12, Chang and 3T3-L1 selle is gekultuur onder standard kondisies en akuut 
blootgestel aan stygende ekstrakkonsentrasies, Water het as kontrole gedien, met 1 μM 
insulien en metformien as positiewe kontroles.. Glukose opname vanuit 8 mM glukose 
kultuurmedia is bepaal deur „n fluorimetriese oksidase metode. Radioaktiewe 14C-glukose-
oksidasie na 14CO2 en die bepaling van die glukogeen inhoud van selle is gebruik om die 
lot van intrasellulêre glukose te bepaal. RT-PKR is gebruik om die effek van die ekstrak op 
die insulien-seinpad geen-uitdrukking te ondersoek. Die antioksidant effek van A. 
phylicoides ekstrak in pankreatiese β-selle geïsoleer van Wistar rotte, is bepaal deur 
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stikstofoksied (NO) produksie na aanleiding van hiperglukemiese kondisies. NO is met 
diaminofluorosien diasetaat gemerk en die fluoresensie gemeet deur vloeisitometrie. 
Insulien afskeiding deur die pankreatiese β-selle is deur radio-immuno metode bepaal. Die 
anti-oksidatiewe effek van die ekstrak op lipopolisakkaried-gestimuleerde perifere 
mononuklêere-selle afkomstig van Wistar rotte is bepaal deur die meting van TNF-α 
produksie met „n ELISA kit. 
Resultate: C2C12 miosiete het „n maksimale toename in glukoseopname by „n 0.05 μg/μl 
ekstrakkonsentrasie (228.3% ± 66.2, p<0.001) gehad. Dieselfde ekstrakkonsentrasie het 
maksimale toename in glukoseopname in Chang selle (134.5% ± 2.5, p<0.05 getoon. In 
3T3-L1 selle is maksimale toename in die glukoseopname by „n konsentrasie van 0.025 
μg/μl (143.5% ± 10.3, p<0.001) bereik. „n Ekstrak-geÏnduseerde verhoging in die 
insulienreseptor en glukosetransporter vier ekspressie is in C2C12 miosiete waargeneem. 
Die oksidasie van 14C-glukose na 14CO2 deur C2C12 miosiete is maksimaal verhoog deur 
akute blootstelling aan die ekstrak by „n konsentrasie van 0.1 μg/μl (2919.3 fmol/1x10^6 
cells ± 428, p<0.01). Die oksidasie van 14C-glukose na 14CO2 deur Chang selle was 
maksimaal verhoog deur akute blootstelling aan die ekstrak by „n konsentrasie van 0.1 
μg/μl (4476.7 fmol/1x10^6 cells ± 1620, p<0.05) soos gevind in die C2C12 selle. Die 
ekstrak het glukogeenstoring verhoog teen al drie die konsentrasies waarteen getoets is in 
Chang selle, maar „n maksimale effek is gevind by „n konsentrasie van 0.025 (13.6 
μg/1x10^6 cells ± 0.7, p<0.05). A. phylicoides ekstrak het nie „n meetbare effek op die 
oksidatiewe status van β-selle of die anti-inflammatoriese status van perifere 
mononuklêere-selle gehad nie. Die ekstrak het wel „n verhoging in die eerstefase 
insuliensekresie van β-selle in hyperglukemiese kondisies gehad, alhoewel die verhoging 
nie statisties betekenisvol was nie. 
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Afleiding: Athrixia phylicoides waterekstrak stimuleer in vitro glukoseopname en 
metabolisme in „n insulin-mimetiese manier, wat beteken dat die ekstrak potensiëel 
voordele vir tiepe twee diabete kan inhou as aanvullingsterapie. 
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INTRODUCTION 
Athrixia phylicoides is an aromatic, indigenous shrub with high antioxidant content and 
numerous indigenous medicinal properties inferred by ingestion of an herbal brew of the 
plant. Recently A. phylicoides has been shown by McGaw et al. (2007) to have similar 
antioxidant activity to Rooibos tea, and a unique, new flavonol (i.e. a polyphenolic 
antioxidant plant metabolite) 5-hydroxy-6,7,8,3′,4′,5′-hexamethoxyflavon-3-ol, unique to A. 
phylicoides, was isolated by Mashimbye et al. in 2006. With changes in the socio-
economic climate and a new trend in merging Western lifestyle with traditional practices, 
new interest has been shown in herbal/natural remedies. Uncovering the scientific basis of 
the remedial effects of natural products has been imperative in providing the 
pharmaceutical industry with “lead” compounds which can be synthesized into new clinical 
therapies (Haslam, 1996). 
 
The socio-economic burden of type two diabetes (T2D) is rapidly increasing, with 
predictions of worldwide prevalence increasing from 2.8% in 2000 to 4.4% in 2030 (Wild et 
al., 2004). T2D is characterized by insulin resistance (Reaven, 1988) and β-cell failure 
(Porte, 1991), a culmination of which leads to abnormalities in glucose and lipid 
metabolism and hyperglycaemia. Reactive oxygen species, which may be 
hyperglycaemia-induced, have been implicated in inducing multiple forms of insulin 
resistance as well as exacerbating known diabetic complications (e.g. cardiovascular 
disease) (Johansen et al., 2005; Houstis et al., 2006). In 1980, Logani and Davies 
suggested that supplementation with non-toxic antioxidants may have a chemoprotective 
role in T2D. If Athrixia phylicoides aqueous extract demonstrates hypoglycaemic and 
antioxidant properties, commercialization of the extract holds great economic and 
developmental potential for the indigenous communities as well as to the health of the 
general populace (Rampedi and Olivier, 2005). The aim of this study was to firstly, 
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determine the in vitro effect of A. phylicoides aqueous extract on glucose metabolism in 
cell lines that mimic the three key organs implicated in glucose homeostasis. Secondly, the 
study aimed to determine the potential ex vivo antioxidant and anti-inflammatory effect of 
the extract in pancreatic β-cells and peripheral mononuclear cells respectively. 
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LITERATURE REVIEW 
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1. Overview of Athrixia phylicoides 
1.1. Physical characteristics and indigenous distribution 
Athrixia phylicoides is an aromatic, indigenous shrub of approximately one meter in height, 
commonly found in the mountainous and grassland areas of the eastern parts of South 
Africa. Distribution includes Mpumalanga, Limpopo, KwaZulu-Natal, Swaziland and 
northern parts of the Eastern Cape (figure 1) (Fox et al., 1982; and Van Wyk and Gericke, 
2000). 
  
Figure 1. Natural geographical distribution of A. phylicoides (grey shaded area) in 
Southern Africa (adapted from Rampedi and Olivier, 2005).  
 
The dense foliage of this member of the Asteraceae family (tribe Gnaphalieae) is 
comprised of fine, linear leaves (dark green and shiny above, and grey/white below) that 
are approximately 30 x 10 mm in size (figure 2) (Van Wyk and Gericke, 2000).  
a.   b.   
Figure 2. Athrixia phylicoides shrub (a) and flowers (b) (Pooley, 1998) 
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Known to flower throughout the year, these plants thrive in a variety of habitats, including 
grassland, forest, bushveld, rocky and sloping environments. Flowers are characteristically 
mauve with distinct yellow disc florets (figure 2b) (Fox et al., 1982; Leistner et al., 2000; 
Van Wyk and Gericke, 2000; and Rampedi and Olivier, 2005). 
 
1.2. Indigenous uses 
A. phylicoides is indigenously referred to as Bush or Zulu tea (English); Boesmanstee 
(Afrikaans); Icholocholo, Itshelo, or Umthsanelo (Zulu). A permutation of the shrub‟s aerial 
foliage and stems is dried and used to produce an herbal tea by certain indigenous African 
people.  It is also chewed by the Sotho and Xhosa for sore throats and coughs (Watt and 
Breyer-Brandwijk, 1932; and van Wyk and Gericke, 2000). The Venda people have been 
reported to use a brew of A. phylicoides as an aphrodisiac (Hutchings et al., 1996; van 
Wyk and Gericke, 2000). The Zulu people use an herbal tea infusion of this shrub for blood 
“purification” and to treat sores and boils (Rampedi and Olivier, 2005; and Hutchings et al., 
1996). In the study by Rampedi and Olivier (2005), South African rural respondents used 
the A. phylicoides tea to treat hypertension, heart disease and diabetes. Medicinal and 
therapeutic value of this plant has yet to be verified scientifically. This indigenous tea is 
mainly produced and used in rural areas, with only informal traders supplying the 
increasing demand in urban areas (Rampedi and Olivier, 2005). Scientific characterisation 
of health benefits of this tea and commercialisation thereof holds economic, developmental 
and therapeutic potential for local communities. 
  
1.3. Toxicity screening 
 Pyrrolizidine alkaloids (PA) are a well-recognized and relatively common group of plant 
toxins that occur in up to 3% flowering plant species, including the Asteraceae family, and 
have numerous adverse health implications (Smith and Culvenor, 1981). McGaw et al. 
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(2007) used spectrophotometric and gas chromatography-mass spectrometry analysis to 
show that the A. phylicoides aqueous extract does not contain PA. Cytotoxicity screening, 
using kidney cell lines and brine shrimp toxicity assays, showed that while the ethanol 
extract was relatively toxic, the aqueous extract was not (McGaw et al., 2007). In addition 
to in vitro screening, in vivo toxicity screening of plant products is important to account for 
potential toxicity of derived plant metabolites. An in vivo sub-chronic toxicity study of A. 
phylicoides aqueous extract using Wistar rats showed no signs of hepato- or biochemical 
toxicity, nor were there adverse anthropological or metabolic effects (Chellan et al., 2008). 
 
1.4. Phenolic composition 
In 1985 Beart et al. considered polyphenolic constituents in tea plants purely a chemical 
defense against birds, insects and animals. Plant-derived flavonoids have subsequently 
been reported as having numerous medicinal properties, such as anti-inflammatory, anti-
mutagenic and anti-bacterial (Hirasawa et al., 2002). Schewe and Sies (2005) and Nijveldt 
et al. (2001) describe flavonoids as being potent antioxidants that are capable of 
scavenging hydroxyl radicals, superoxide anions as well as lipid peroxyl radicals. 
 
Recently, A. phylicoides has been shown by McGaw et al. (2007) to have similar 
antioxidant activity to Rooibos tea, and may well have commercial benefits in addition to its 
horticultural potential. It has long been known that the health benefits attributed to certain 
herbal teas are due to the tea‟s antioxidant properties, such as those inferred by the 
phenolic composition of rooibos tea (Niwa and Miyachie 1986). Numerous health benefits 
attributed to the antioxidant properties of polyphenols, particularly flavonoids (Niwa and 
Miyachie, 1986), include protection against cellular oxidative damage, due to the ability of 
antioxidants from the plant to scavenge free radicals. An epidemiological study by Arts and 
Hollman (2005) illustrated the relationship between the intake of flavonoids and a 
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reduction on the risk of degenerative diseases such as type II diabetes. 
 
Numerous medicinal plants have demonstrated pharmacological actions in lowering blood 
glucose and/or stimulating insulin secretion; this has been attributed to their rich content of 
bioactive chemicals such as terpenoids, flavonoids and phenolics (Jung et al., 2006). A 
unique, new flavonol (i.e. a polyphenolic antioxidant plant metabolite) 5-hydroxy-
6,7,8,3′,4′,5′-hexamethoxyflavon-3-ol (figure 3) was isolated from A. phylicoides 
(Mashimbye et al., 2006). Haslam (1996) reported that the anti-oxidative properties of both 
green (unfermented) tea and red wine are based on their high yield of polyphenols that are 
based on the flavon-3-ol carbon oxygen skeleton. 
 
 
 
Figure 3. 5-hydroxy-6,7,8,3′,4′,5′-hexamethoxyflavon-3-ol (Mashimbye et al., 2006) 
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2. Glucose metabolism 
The cellular process of glycolysis is responsible for the conversion of glucose (C6H12O6) 
into pyruvate (CH3COCOO
- + H+). Glucose that has entered the cell undergoes a series of 
insulin-induced enzymatic reactions, which include glucose phosphorylation, glycogen 
synthesis and glucose oxidation (DeFronzo, 2004). The free energy released from this 
process is used to fuel cells by forming high energy adenosine triphosphate (ATP) and 
reduced nicotinamide adenine dinucleotide (NADH) (Ganong, 1989). Once in the cell, 
glucose is phosphorylated by hexokinase to form glucose-6-phosphate. An additional 
glucose phosphorylating enzyme, glucokinase, is found in the liver and is increased by 
insulin stimulation. The glucose-6-phosphate is either stored (polymerized into glycogen or 
converted to fat) or catabolised in the glycolytic pathway (figure 4) to produce energy 
(Ganong, 1989; and Mathews et al., 2000). 
 
                                  
 
 + 2 [NAD]+ + 2 [ADP] + 2 [P]I                  + 2 [NADH] + 2 H
+ + 2 [ATP] 
     
 
     Glucose            Pyruvate + Energy 
 
Figure 4. Glycolytic reduction of glucose to pyruvate and energy (ATP and NADH) 
 
2.1. Glucose metabolism in skeletal muscle, fat and liver 
Mathews et al. (2000) describe the brain as the largest consumer of glucose, whereas 
glucose homeostasis is maintained by three key organs/tissues; i.e. skeletal muscle, liver 
and fat/adipose. The brain uses approximately 50% of total glucose taken up in an insulin 
independent manner (DeFronzo, 2004). The liver and gastrointestinal tissues (responsible 
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for approximately 25% glucose usage) also use glucose in an insulin independent manner. 
Glucose uptake in skeletal muscle and adipose tissues is insulin-stimulated, with 
approximately 80-85% of glucose uptake in peripheral tissues occurring in the muscle 
(DeFronzo, 2004).  
 
In skeletal muscle glucose is primarily oxidized for energy and secondarily stores glucose 
as glycogen. Glucose taken up is converted to lactate by glycolysis or stored as glycogen 
(Cartailler, 2001; and DeFronzo, 2004). At low glucose concentrations and in starvation 
states, skeletal muscle mobilizes fatty acids by β-oxidation and/or ketogenesis; glycogen 
stores are also mobilized by glycogenolysis. In the starved state proteins are also broken 
down (proteolysis) to amino acids (Ganong, 1989; and DeFronzo, 2004). 
 
The liver acts as a glucose sensing device, as determined by glucose transporters of the 
subclass two (GLUT2) found in hepatocytes. In addition, the liver is responsible for 
glucose production (hepatic glucose production, HGP) (DeFronzo, 2004; and Chakraborty, 
2006). The liver responds to an increase in circulating glucose by converting glucose to 
storage polymers (glycogen and triacylglycerols). At low glucose concentrations, the liver 
provides energy substrate by mobilising fatty acids by β-oxidation and glycogen by 
glycogenolysis. During a period of starvation, the liver also converts amino acids to 
glucose by gluconeogenesis (Ganong, 1989; Cartailler, 2001; DeFronzo, 2004; and 
Chakraborty, 2006). 
 
Adipose tissues primarily convert glucose to triglycerides for storage. Stored 
triacylglyerides are mobilized in states of low glucose and/or starvation (Cartailler, 2001). 
Although adipose tissue is responsible for only 4-5% of glucose disposal in peripheral 
tissues, it still plays a key role in glucose homeostasis as well as the development of 
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defects in glucose metabolism. Adipose tissues secrete adipocytokines and regulate the 
release of free fatty acids (FFA) from stored triglycerides; both adipocytokines and FFA 
influence insulin sensitivity in muscle and liver (Ganong, 1989; and DeFronzo, 2004). 
 
2.2. Key Hormones regulating glucose homeostasis 
Insulin is a hormonal protein synthesized by pancreatic beta-cells (β-cells) in the islets of 
Langerhans (Mathews et al., 2000). Biochemical actions of insulin include increasing 
muscle and fat cell permeability to glucose by facilitating the translocation of glucose 
transporter four   (GLUT4) to the cell membrane. Insulin also increases the processes of 
glycolysis (glucose catabolism), glycogenesis (glycogen synthesis), triacylglycerol 
synthesis and protein, DNA and RNA synthesis (Mathews et al., 2000). In the liver, insulin 
decreases gluconeogenesis and glycogenolysis (figure 5). 
 
 
Figure 5. Regulation of glucose homestasis by pancreatic hormones insulin and 
glucagon. Insulin promotes glucose uptake, catabolism and storage, whereas glucagon 
promotes mobilization of stored glucose, primarily from the liver and adipose tissues 
(Freudenrich, 2001). 
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One of the mechanisms by which insulin decreases HGP is by inhibiting glucagon 
secretion in the pancreas, this results is decreased gluconeogenesis (DeFronzo, 2004). 
Schulman (2000) and Sesti (2006) describe the ability of insulin to increase the rate of 
glucose uptake in skeletal muscle and adipose tissue, this is preceded by insulin-
stimulated translocation of GLUT4. Insulin also regulates glycogen synthase in the muscle, 
controlling the rate of glycogen synthesis (Dent et al., 1990 and DeFronzo, 2004). In 
adipose tissue, insulin increases lipid synthesis and decreases FFA release (Shulman, 
2000; and Sesti, 2006). Insulin-induced decrease in lipolysis decreases the amount of 
circulating FFA (DeFronzo, 2004). Insulin is considered a growth hormone because of its 
ability to promote biosynthesis (e.g. proteins, DNA etc.). Insulin resistance is characterized 
by decreased glucose transport (Sesti, 2006), whereby normal circulating insulin 
concentrations fail to stimulate glucose uptake (Chakraborty, 2006). 
 
Glucagon is also synthesized by pancreatic cells in the islets of Langerhans, known as 
alpha-cells (α-cells). Glucagon is secreted in response to low circulating glucose 
concentrations, with its primary target being the liver. In the liver, glucagon promotes 
glycogenolysis (breakdown of glycogen) and inhibits glycogenesis (synthesis and storage 
of glycogen polymers) (figure 5). Glucagon also promotes the mobilization of triacylglycerol 
in adipose tissue (Mathews et al., 2000). 
 
Epinephrine, secreted by the adrenal medulla, regulates glucose homeostasis by 
activating glycogenolysis and inhibiting glycogenesis in response to low circulating glucose 
levels (Mathews et al., 2000). 
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2.1. Insulin signalling 
Insulin is an anabolic hormone involved in the regulation of glucose homeostasis. 
Synthesis and secretion of insulin is further discussed in section 2.2.1. Insulin is secreted 
in response to a rise in blood glucose levels. At a cellular level, glucose uptake is mediated 
through glucose transporters. GLUT4 is the insulin-responsive transporter of glucose in 
various cell types in the body, including adipose and muscle cells (Brunetti, 1989, and 
Nedachi and Kanzaki, 2006). As illustrated in figure 6 below, insulin binds to the 
transmembrane insulin receptor (INSR) leading to activation of the insulin receptor intrinsic 
tyrosine kinase. Insulin receptor substrates one and two (IRS1/2) undergo phosphorylation 
of their tyrosine residues. Phosphorylated IRS proteins serve as multisite docking proteins 
for various effector molecules including the p85 regulatory subunit of phosphoinositide 3-
kinase (PI3K). Multiple downstream effectors result in rapid incorporation of GLUT4 
transporters from a cytoplasmic pool to the cell membrane (figure 6) (Nedachi and 
Kanzaki, 2006; and Sesti 2006).  
 
 
Figure 6. Insulin-mediated GLUT-4 translocation and subsequent glucose uptake 
into the cell. (Cartailler, 2001) 
 
cytosol 
11 | 
 
GLUT4 is the main transmembrane glucose transporter in stimulated glucose uptake in 
muscle and adipose cells. Basal glucose uptake is regulated by the ubiquitous glucose 
transporter one (GLUT1) in these cells, as well as glucose sensing GLUT2 in liver and β-
cells (Cartailler, 2001; and Nedachi and Kanzaki, 2006). 
 
2.1.1. Defects in type two diabetes mellitus 
The socio-economic burden of type two diabetes (T2D) is rapidly increasing, with 
predictions of worldwide prevalence increasing from 2.8% in 2000 to 4.4% in 2030 (Wild et 
al., 2004). T2D is characterized by insulin resistance (Reaven, 1988), β-cell failure (Porte, 
1991), chronic hyperglycaemia and disturbances in carbohydrate, lipid and protein 
metabolism (Duckworth, 2001). Insulin resistance in the muscle and liver is characteristic 
in T2D (DeFronzo, 2004). Despite hyperinsulinemia in the insulin resistant state, the liver 
continues overproduction of glucose. Insulin-mediated suppression of gluconeogenesis is 
defective in insulin resistant liver, resulting in increased HGP which further exacerbates 
the hyperglycaemic conition (DeFronzo, 2004). In T2D, the ability of insulin to inhibit lipase 
in adipose tissue is reduced (Bays, 2004). The lipase enzyme is responsible for lipolysis in 
adipose tissue; a process whereby stored triglycerides are released/broken down into FFA 
and glycerol (Bays, 2004; DeFronzo, 2004; and Chakraborty, 2006). Insulin resistant and 
T2D patients have been shown to have chronically elevated levels of circulating FFA, 
which have been demonstrated to be responsible for insulin resistance in muscle and liver 
(Boden, 1997). Furthermore, chronically elevated FFA impairs insulin secretion (Boden, 
1997; and DeFronzo, 2004). 
 
Overt or full blown T2D only develops once the pancreatic β-cells can no longer 
compensate for the hyperinsulinemic requirement in order to maintain glucose 
homeostasis. Hyperglycaemia ensues, resulting in a cascade of deleterious physiological 
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effects including β-cell failure, microvasulature damage, cardiovascular disease, 
neuropathy and retinopathy (Porte, 1991; and Rahimi et al., 2005). Mediators of 
hyperglycemic induced damage include pro-inflammatory cytokines (e.g. tumor necrosis 
factor alpha, TNF-α) as well as reactive oxygen and nitrogen species (ROS and RNS 
respectively). 
 
Insulin-signalling defects in T2D include impaired tyrosine phosphorylation of INSR and 
IRS1/2 upon insulin stimulation, as well as attenuation of the association of the p85 sub 
unit of PI3K with IRS1/2 (Cusi et al., 2000). Insulin‟s potential to induce the translocation of 
GLUT4 from intracellular organelles to the plasma membrane is defective in insulin 
resistant individuals, thus not facilitating glucose uptake into muscle (and fat) (Bryant et al., 
2002; Hoehn et al., 2008). 
 
2.1.2. Role of oxidative stress in type two diabetes mellitus 
ROS (and FFA) are proposed to be mediated by intracellular pathways involving several 
signalling molecules, of which nuclear factor-κB (NF-κB) is one (Bastard et al., 2006). 
These intracellular pathways interact directly with insulin signalling via serine/threonine 
inhibitory phosphorylation of IRS via the PI3K/protein kinase B (Akt) pathway (Hotamisligil, 
2003; Bastard et al., 2006). The competitive phosphorylation of IRS inhibits the insulin 
signalling pathway, causing a reduction in the stimulatory capacity of secreted insulin. 
 
Despite the evolution of internal anti-oxidant defense systems (e.g. small-molecule anti-
oxidants, anti-oxidant enzymes and physical barriers), man is still faced with the 
deleterious consequences of ROS. ROS generated as a result of glucotoxicity (i.e. chronic 
hyperglycaemia) exert their deleterious effects on deoxyribonucleic acids (DNA), proteins 
and other biological components through the abstraction of hydrogen atoms, electron 
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transfer and addition reactions (Zhang et al., 2010).  
 
Under normal physiological conditions, key sites of superoxide formation in the 
mitochondrial membrane are complex one and the ubiquinone-complex three interface. 
During energy transduction, a small number of electrons “leak” to oxygen prematurely, 
forming ROS as opposed to oxygen being reduced to water. Diabetes alters these primary 
sites of superoxide formation so that complex two becomes the primary source of 
electrons contributing to superoxide formation. This results in a dangerous increase in the 
normally small amounts ROS produced through “leaking” (Valko et al., 2007). In a study by 
Gurgul et al. (2004) the main source of ROS in the β-cell is attributed to the mitochondrial 
electron transport chain. Ling et al. (2001) describe glucose reacting directly with free 
amine groups on protein and lipids, finally yielding a diverse group of modifications 
referred to as advanced glycation end products (AGE). AGE‟s act via mitochondrial 
complex three, resulting in increased ROS production in response to hyperglycaemia. 
 
Li and Shah (2003) describe several lines of evidence supporting nicotinamide adenine 
dinucleotide phosphate (NADPH) oxidases (through its membrane bound components) as 
major sources of glucose-induced ROS production in vasculature and kidney cells. Butler 
et al. (2000) proposed xanthine oxidase (XO) as a major source of ROS. Treatment of 
non-insulin dependent T2D patients with a XO inhibitor reduced levels of oxidized lipids in 
plasma and improved blood flow. Diabetes is also associated with increased lipoxygenase 
expression; this results in eicosanoid formation (a process involving natural release of 
additional ROS) (Brash, 1999). 
 
Hyperglycaemia-induced oxidative stress has also been observed in non-nucleated cells 
that lack mitochondria and NADPH oxidase (e.g. erythrocytes). Robertson and colleagues 
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(2003) have considered glucose auto-oxidation as another mechanism of ROS production. 
Whereby glucose itself (and its metabolites) reacts with hydrogen peroxide in the presence 
of iron and copper ions to form hydroxyl radicals (shown by in vitro studies only). 
 
2.1.3. Role of inflammation in type two diabetes mellitus 
The inflammatory state is characterised by secretion of inflammatory cytokines and ROS 
(Crouvezier et al., 2001). Insulin-stimulated phosphorylation of IRS proteins is the crucially 
defective step in most cases of systemic insulin resistance (Wellen and Hotamisligil, 
2005). Pro-inflammatory effects of cytokines (e.g. TNF-ά), as well as ROS and FFA, are 
proposed to be mediated by intracellular pathways involving several signalling molecules, 
of which NF-κB is one (Bastard et al., 2006). These intracellular pathways interact with 
insulin signalling via serine/threonine inhibitory phosphorylation of IRS via the PI3K/Akt 
pathway (Hotamisligil, 2003; Bastard, 2006).  
 
Kaddai et al. (2009) propose that decreased glucose transport in adipocytes from insulin 
resistant patients could be as a result of decreased GLUT4 levels as well as GLUT4 
mislocalisation. This mislocalisation was attributed to a negative correlation between TNF-
ά and sortilin one (Sort1) expression (as shown in 3T3-L1 and human adipocytes in vitro, 
and in vivo in mice epididymal tissue and subcutaneous tissue of morbidly obese diabetic 
patients). The role of TNF-ά (as a result of chronic low-grade inflammation) on Sort1 
expression may result in increased lipotoxic effects (adipocyte hypertrophy) since sortilin 
facilitates lipoprotein lipase degradation in muscle (Nielsen et al., 1999). Sortilin is also a 
co-receptor for the p75 nerotrophin receptor (p75NTR) and is thus involved in the insulin-
responsive glucose transport system in muscle (Ariga et al., 2008). 
 
It is known that TNF-ά stimulates the secretion of interleukin-6 (IL-6) in adipocytes (Rotter 
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et al., 2003). It has subsequently been demonstrated in 3T3-L1 cells that IL-6 inhibits 
mRNA expression of GLUT4 and largely increases the expression of GLUT1 (Rotter et al., 
2003; Kaddai et al., 2009). 
 
2.2. Defects in pancreatic β-cells in type two diabetes mellitus 
2.2.1. Physiology of the endocrine pancreas 
The endocrine pancreatic islets of Langerhans are morphologically distinct from the rest of 
the exocrine pancreatic tissue; they form rounded clusters of cells (figure 7) throughout the 
pancreas, particularly in the tail (Nunemaker and Satin, 2005; and Stevens and Lowe, 
2005).  
 
a.          b.  
  β-cell;            δ-cell;           α-cell;           capillary 
 
 
Figure 7. Pancreatic islets of Langerhans. Cellular composition (modified from 
Nunemaker and Satin, 2005) (a) and histological section stained for insulin (red) and 
glucagon (brown) at 200 x magnification (Diabetes Discovery Platform, 2010) (b). 
 
The islets are comprised of three main cellular components; i.e. insulin and amylin 
secreting β-cells, glucagon secreting α-cells and somatostatin secreting delta-cells (δ-
cells). Some pancreatic polypeptide secreting PP cells are also found within pancreatic 
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islets (Nunemaker and Satin, 2005; and Stevens and Lowe, 2005). 
 
Insulin secretion in β-cells is triggered by rising blood glucose levels. GLUT2 senses and 
transports glucose into the β-cell. Glucose is then phosphorylated, causing a rise in the 
ATP to adenosine diphosphate (ADP) ratio (figure 8). This rise inactivates the potassium 
channels, resulting in depolarization of the cell membrane. The calcium channels open, 
allowing calcium ions to flow into the cell. The ensuing influx of calcium leads to the 
exocytotic release of insulin from storage granules (Cartailler, 2001). 
 
 
Figure 8. Glucose stimulated insulin secretion in pancreatic β-cells (Cartailer, 2001). 
 
2.2.1. β-cell failure and type two diabetes 
β-cell failure is characteristic of T2D, with further deterioration that occurs during the 
natural course of the disease (Porte, 1991). T2D, as characterized by hyperglycaemia and 
dyslipidemia, develops when pancreatic β-cells can no longer compensate for the 
hyperinsulinemic requirement in the preceding insulin resistant state (DeFronzo, 2004). 
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Autopsy studies by Butler et al. (2003) revealed that β-cell neogenesis is not impaired in 
T2D patients, however increased apoptosis is evident. Suggested factors involved in this 
neogenesis/apoptosis imbalance include glucotoxicity, insulin resistance within the β-cells, 
inflammation and oxidative stress (Bonora, 2008). Apart from suppressed insulin response 
to glucose, islets from T2D were observed to have lower rates of glucose oxidation 
(Marchetti et al., 2006). Hyperglycaemia has been seen to exacerbate β-cell inflammation 
and oxidative stress. One of the mechanisms is via the NF-κB pathway which results in 
increased local expression of inflammatory cytokines (e.g. TNF-ά) (Marchetti et al., 2006 
and Bonora, 2008).  
 
One of the hypotheses for induction of β-cell dysfunction focuses on changes in the 
expression and function of a mitochondrial inner membrane protein, uncoupling protein 
two (UCP2). Krauss et al. (2003) proposed UCP2 activity and expression contribute to an 
increase in superoxide formation under diabetic conditions. β-cells are particularly 
sensitive to ROS since they contain low levels of free-radical quenching enzymes such as 
glutathione peroxidase and superoxide dismutase (Abdollahi et al., 2004). 
 
Brownlee (2003) also demonstrated that hyperglycaemia increased free radical 
concentration in human islets. Treatment of Zucker fatty rats with antioxidant agents (e.g. 
N-acetylcisteine and aminoguanidine) prevented abnormalities in insulin gene expression 
and hyperglycaemia-induced loss of transcription factors (e.g. pancreatic homeobox one, 
PDX-1) (Tannaka et al., 1999). 
 
Since one of the main sources of ROS in the β-cell is attributed to the mitochondrial 
electron transport chain (Gurgul et al., 2004), chronic stimulation of insulin secretion 
(induced by hyperglycaemia) increases ROS production and hence oxidative stress. 
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Changes in β-cell function, as a result of hyperglycaemia, may also be explained by the 
activation of the endoplasmic reticulum (ER) stress pathway as well as by sustained 
elevation of cystolic calcium concentrations (Grill and Bjorklund, 2001). 
 
Kahler et al. (1993), implicate free radicals (which include the superoxide, hydroxy, 
hydrogen peroxide and lipid peroxide radicals) in the disease process of T2D. It is known 
that these ROS are produced as part of the normal biochemical and physiological 
processes of the body (Arabbi et al., 2004). Increased exposure to adverse environmental 
and/or dietary xenobiotics (e.g. hyperglycaemia) may increase the production of ROS 
(Johansen et al., 2005). Long term complications of T2D may be exacerbated by oxygen-
free radical activity (e.g. RNS) which can initiate peroxidation of lipids, which in turn 
stimulates glycation of protein, inactivation of enzymes and alteraltions in the structure and 
function of cell membranes (Boynes, 1991). Oxidative stress is described as being the 
result of an imbalance between the generation of oxygen and nitrogen derived radicals 
and an organism‟s antioxidant potential (Abdollahi et al., 2004), may validate Logani and 
Davies‟ suggestion in 1980 that supplementation with non-toxic antioxidants may have a 
chemoprotective role in T2D. 
 
2.2.1. The role of nitric oxide in glucose-stimulated insulin secretion and β-cell 
oxidative stress 
Nitric oxide (NO) plays an ambiguous role in physiology in that it is both essential for 
execution of some physiological processes (e.g. as an endothelial derived relaxing factor 
and as an intermediate in the synthesis and secretion of insulin at low micromolar 
concentrations) and that it can be toxic in excess. NO was seen to stimulate insulin gene 
expression, PI3K activity in both Min6 and freshly isolated pancreatic islets (Campbell et 
al., 2007). NO is most deleterious once it reacts with superoxide radicals to form 
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peroxynitrite (Paquay et al., 2000). Hyperglycaemia is linked with the regulation of NOS 
expression and the production of peroxynitrite. Protein kinase C activation has been 
shown by Hink et al. (2001) to be a key event in hyperglycaemia-induced NOS 
upregulation (perhaps mediated by NF-κB).  Under in vitro conditions, cytokines (e.g. TNF-
α, IL-1β) have been demonstrated to increase expression of inducible nitric oxide (iNOS), 
leading to the generation of NO. Concomitant translocation of NF-κB to the β-cell nucleus 
results in cell death (Kanitkar et al., 2008). 
 
2.3. In vitro assay models 
In vitro screening assays offer the ability to screen for pharmacokinetic activity of 
compounds/molecules within a specific, cell type (Van de Venter et al., 2008). Muscle 
derived cell lines, including C2C12 myocyte, and fibroblast derived 3T3-L1 adipocytes, 
have been shown to be sensitive to insulin stimulation in culture resulting in an increase of 
GLUT4 translocation and glucose uptake from the culture medium (Brunetti, 1989, and 
Nedachi and Kanzaki, 2006). These cell lines mimic main tissues involved in peripheral 
insulin regulated glucose homeostasis and utilisation in mammals, namely muscle and fat. 
3T3-L1 adipocytes have also been extensively used in metabolic disease research for over 
30 years. These cells have been described as being pivotal in advancing the 
understanding of basic cellular mechanisms associated with diabetes and related 
disorders. (ZenBio Inc. 2010). Liver cells, including Chang cells, in contrast to muscle 
cells, have non-insulin-sensitive glucose transporters and are less sensitive to acute 
insulin stimulated glucose uptake. Chang cells are a human liver derived epithelial and 
non-tumorgenic cell line that have been shown to express insulin receptor (Rengarajan et 
al., 2007) and to be responsive to insulin stimulation (Parthasarathy et al., 2009). 
 
Erasto et al. (2009) demonstrate the ability of all three of the above mentioned cell lines 
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(i.e. C2C12, Chang and 3T3-L1 cells) to be responsive to extract-stimulated glucose 
uptake. C2C12 and 3T3-L1 cells responded to insulin stimulation by increasing glucose 
uptake, and Chang cells exhibited a similar increase in glucose taken up when stimulated 
with metformin (Erasto et al., 2009). 
 
2.4. Current therapies in type two diabetes mellitus 
In a review by Jung and colleagues (2006), the authors describe the mechanisms of 
current T2D therapeutics (both clinical and nutraceuticals). These mechanisms include the 
ability of an agent to directly stimulate insulin secretion, to inhibit increased release of 
glucose into the blood (e.g. by inhibition of α-glucosidase, a hormone that facilitates the 
breakdown of carbohydrates to sugar, or by inhibition of glycogenolysis and 
gluconeogenesis), to enhance glucose utilisation (e.g. by increasing the concentration and 
sensitivity of insulin receptors) (Jia et al., 2003 and Jung et al., 2006). Further ability to 
reduce free radicals and improve microcirculation offers added benefit to T2D patients 
(Jung et al., 2006).  
 
2.4.1. Clinical pharmacological agents 
DeFronzo (2010) describes the goal of pharmacological therapy in T2D as being 
multifactoral; there should be therapeutic delay in disease progression as well as treat the 
multiple pathophysiological mechanisms associated with T2D. Insulin therapy and the anti-
diabetic drug metformin are commercially available and well characterized treatments for 
T2D and the latter for insulin resistance (Pearson, 2009, and DeFronzo, 2010). Other oral 
therapeutic agents include the thiazolidinediones (TZDs), incretin-mimetics and 
sulfonylureas (Radziuk et al., 2003; Pearson, 2009, and DeFronzo, 2010). 
 
Exogenous insulin therapy regulates glucose homeostasis in a similar way to endogenous 
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insulin secretion. Subcutaneous injection of synthetic insulin decreases HGP (by 
decreasing gluconeogenesis and glycogenolysis), increases peripheral glucose uptake (in 
muscle and adipose tissue) and increases lipid synthesis in liver and adipose tissue 
(Chakraborty, 2006, and DeFronzo, 2010). Risk of hypoglycemia is increased in patients 
on acute insulin therapy (rapid acting synthetic insulins) since exogenous insulin does not 
only facilitate increased glucose uptake from the blood, but also suppresses HGP (Gram 
et al., 2010). A study by Azar and Lyons (2010) proposed that insulin therapy may confer 
added risk for cancer, which may be mediated by signalling through insulin-like growth 
factor one receptor. 
 
Metformin (and TZDs) act by increasing peripheral insulin sensitivity, as well as by 
decreasing hepatic gluconeogenesis (Radziuk et al., 2003; and DeFronzo, 2010).  
Metformin has been reported to be active in several different physiological mechanisms 
which result in amelioration of T2D defects (Perriello et al., 1994; Radziuk et al., 2003; and 
DeFronzo 2010). Radziuk et al. (2003) described metformin as having a mild ability to 
inhibit complex one in the mitochondrial respiratory chain. Inhibition of the respiratory 
chain upregulates expression of GLUT4 and glycolysis in peripheral tissues (Radziuk et 
al., 2003). Perriello and colleagues (1994) implicate the role of metformin in improving 
systemic lipidemia, lowering circulating FFA thus decreasing fatty acid oxidation. FFA have 
been implicated in contributing to hyperglycaemia by stimulating gluconeogenesis (Randle 
et al., 1963). Another implication of metformin is in regulation of 5' adenosine 
monophosphate-activated protein kinase, which plays a role in the stimulation of skeletal 
muscle fatty acid oxidation and glucose uptake, as well as in the modulation of insulin 
secretion by pancreatic β-cells (Radziuk et al., 2003). With glucose transporters, as well as 
insulin receptors, being active in cell membranes, membrane integrity is important with 
fluidity and protein configurations being disturbed in T2D (DeFronzo, 2010). Wiernsperger 
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(1999) described the ability of metformin to modify the physical state of cell membranes 
and their related proteins. 
 
2.4.2. Phytotherapy and antioxidant supplementation in type two diabetes mellitus 
More than 70% of the South African population use indigenous medicinal plants for either 
their own health care needs or in cultural practices (van Wyk and Gericke, 2000, and 
Rampedi and Olivier, 2005). With changes in the socio-economic climate and a new trend 
in merging Western lifestyle with traditional practices, new interest has been shown in 
herbal/natural remedies (Mander et al., 1997). Li et al. (2004) describe negative side 
effects of some synthetic anti-diabetic drugs, such as lactic acid intoxication and 
gastrointestinal upsets. The pharmaceutical industry faces a challenge in that the number 
of new drugs launched into the market declined by 50% since 1995 (Zhang et al., 2010). 
This lack of development of clinical therapy provides a window of opportunity for the 
evolution of new therapeutics to keep up with the current trend towards increased risk of 
degenerative diseases (like T2D and cardiovascular disease) caused by increased 
oxidative stress due to lifestyle. Uncovering the scientific basis of potential ameliorative 
effects of natural products has been important in providing the pharmaceutical industry 
with “lead” compounds which can be synthesized into new clinical therapies (Haslam, 
1996).  
 
2.4.2.1. The antidiabetic and/or antioxidant effects of plant extracts in vitro and in 
vivo 
An in vitro study by Erasto et al. (2009) demonstrated the ability of Vernonia amygdalina (a 
member of the Asteraceae family to which A. phylicoides belongs) to stimulate glucose 
uptake in cell lines that mimic muscle, liver and adipose (i.e. C2C12, Chang and 3T3-L1). 
Another extract from a plant in the Asteraceae family, Stevia rebaudiana Bertoni, directly 
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stimulates pancreatic β-cell insulin secretion (Jeppesen et al., 2000). 
 
An in vivo study by Cao et al. (2007) has shown green tea extract as a regulator of gene 
expression in the glucose uptake (e.g. increase in GLUT2 and GLUT4 expression) and 
insulin signalling (e.g. increase in IRS1 and IRS2 expression) pathways.  
 
Leopoldini et al. (2004) reported that polyphenols derived from green (unfermented) tea 
(e.g. epicatechins) demonstrate strong anti-oxidant properties, particularly against linoleic 
acid peroxidation in homogenous solutions. Tea preparations have also been 
demonstrated to react directly with various types of ROS, such as superoxide radical, 
peroxy radical, NO and peroxynitrite (Sang et al., 2007). Hashimoto et al., (2000) 
demonstrated the metal ion chelating ability of green tea. Chelating of metal ions prevents 
further generation of free radicals. 
 
A study by Kim et al. (1999) demonstrated the ability of flavonoids to inhibit production of 
NO. If this effect can be replicated in pancreatic β-cells, these cells may be afforded a 
period of protection from hyperglycaemia induced stress, with the potential to preserve 
insulin synthetic and secretion properties. 
 
Curcumin, a polyphenolic flavonoid recognized for its potent antioxidant capabilities, has 
been shown to protect pancreatic islets in vitro from cytokine-induced cell dysfunction and 
death (Kanitkar et al., 2007). Using lipopolysaccharide-activated macrophages, 
isothiocyanate and its indole derivatives (from cruciferous vegetables) have also been 
shown to have anti-inflammatory properties (Tsai et al., 2010). 
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3. Study Aim 
The aims of this study were to determine: 
 
 The in vitro effect of A. phylicoides aqueous extract on glucose metabolism in cell lines 
that mimic the three key organs implicated in glucose homeostasis; i.e. muscle (C2C12 
myocytes), liver (Chang cells)  and adipose tissue (3T3-L1 adipocytes). 
 
 The effect of A. phylicoides extract on insulin sensitivity in vitro by measuring the 
expression of genetic markers involved in the insulin signalling cascade. 
 
 The potential ex vivo antioxidant and anti-inflammatory effect of the extract in 
pancreatic β-cells and peripheral mononuclear cells respectively. 
 
 The effect of A. phylicoides extract on cultured pancreatic β-cell insulin secretion. 
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CHAPTER 2 
MATERIALS AND METHODOLOGY 
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MATERIALS 
1. Reagents 
1.1. In vitro experiment reagents 
0.3 M NaOH + 1% sodium dodecyl sulphate (SDS) (prepared in the laboratory according 
to standard protocol; see Appendix I). 
- NaOH (Cat No.: 10252; AnalaR Laboratories, Poole, England), 
- SDS (Cat No.: 161-0416; BioRad, CA, USA). 
 
1,1-Dimethylbiguanide hydrochloride (metformin) (Cat No.: D150959; Sigma, Stanheim, 
Germany). 
 
3-Isobutyl-1-methylxanthine (IBMX) (Cat No.: I7018; Sigma, Stanheim, Germany). 
 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (Cat No.: M5655; 
Sigma, Stanheim, Germany). 
 
Absolute ethanol (molecular grade) (Cat No.: E7023; Sigma, Manheim, Germany). 
 
Agilent RNA 6000 Nano kit (Cat No.: 5067-1511; Agilent Technologies, Waldbronn, 
Germany). 
 
Biovision Assay Kits: 
- Glucose Uptake Assay Kit (Cat No.: K606-100; BioVision Incorporated, CA, USA), 
- Glycogen Content Kit (Cat No.: K646-100; BioVision Incorporated, CA, USA). 
 
Bovine serum albumin (BSA) (Cat No.: A4919; Sigma, Stanheim, Germany). 
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Bradford assay kit (Cat No.: 3#500-0203; Bradford BioRad Assay, BioRad Laboratories, 
California, USA). 
 
Cell culture tested water (Cat No.: W3500; Sigma, Stanheim, Germany). 
 
Cell lines: 
- C2C12 (Cat No.: CRL-1772; American Type Culture Collection, VA, USA), 
- Chang (Cat No.:  CCL-13; American Type Culture Collection, VA, USA), 
- 3T3-L1 (Cat No.:  CL-173; American Type Culture Collection, VA, USA). 
 
Chloroform (Cat No.: C2432; Sigma, Manheim, Germany). 
 
Dexamethasone (Cat No.: D4902; Sigma, Stanheim, Germany). 
 
D-glucose (Cat No.: G7021; Sigma, Stanheim, Germany). 
 
Dimethyl sulfoxide (DMSO) (Cat No.: D4540; Sigma, Stanheim, Germany) 
 
Dulbecco‟s modified Eagle‟s medium base (Cat No.: D5030; Sigma, Stanheim, Germany). 
 
Dulbecco‟s modified eagle‟s medium (DMEM) (Cat No.: 12-741F, Lonza, MD, USA) (See 
Appendix I for constituents). 
 
Dulbecco‟s phosphate buffered saline (DPBS) (Cat No.: 17-513, Lonza, MD, USA). 
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Eagle‟s modified essential medium (EMEM) (Cat No.: 12-662F, Lonza, MD, USA). (See 
Appendix I for constituents). 
 
GenElute™ Mammalian Total RNA kit (Cat No.: RTN350; Sigma, Stanheim, Germany). 
 
Glucose-D-[14C (U)] (Cat No.: NECO42X050UC, Perkin Elmer, MA, USA). 
 
Heat inactivated fetal calf serum (FCS) (Cat No.: 1050-064; GIBCO, Invitrogen, Auckland, 
New Zealand). 
 
High capacity cDNA kit (Cat No.: 4369913; Applied Biosystems, CA, USA). 
 
Horse serum (HS) (Cat No.: 14-103E, Lonza, MD, USA). 
 
Insulin solution from bovine pancreas; 10 mg/ml in 25 mM HEPES buffer, pH8.2 (Cat No.: 
I0516; Sigma, Stanheim, Germany). 
 
Isopropanol (Cat No.: I9516; Sigma, Manheim, Germany). 
 
Millex GP syringe-driven filter units (Cat No.: SLGP033RS; Millipore, MA, USA). 
 
NaHCO3 (Cat No.: S3817; Sigma, Stanheim, Germany). 
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Polymerase chain reaction probes (Applied Biosystems, CA, USA): 
- Insulin receptor (INSR); Human (Accession No.: NM_000208.2), mouse (Accession 
No.: NM_010568) 
- Insulin receptor substrate one (IRS1); Human (Accession No.: NM_005544.2), 
mouse (Accession No.: NM_010570) 
- Insulin receptor substrate two (IRS2); Human (Accession No.: NM_003749.2), 
mouse (Accession No.: NM_001081212.1) 
- Phosphoinositide-3-kinase (PI3K); Human (Accession No.: NM_181523.1), mouse 
(Accession No.: NM_001024955.1) 
- Glucose transporter four (GLUT4); (Accession No.: NM_001042), mouse 
(Accession No.: NM_009204.2) 
- Beta Actin (ActB); Human (Part No.: 4326315E-0805013), mouse (Part No.: 
4352341E-0808009) 
- Glyceraldehyde 3-phosphate dehydrogenase (GAPDH); Human (Part No.: 
4326317E-0810028), mouse (Part No.: 4352339E-0806018) 
 
Power SYBR Green (Cat No.: 4367659; Applied Biosystems, CA, USA). 
 
RNase-free water (Cat No.: 1039480; Qiagen, Hilden, Germany). 
  
RNase-free wipes (Cat No.: 9786; Ambion, Applied Biosystems, CA, USA). 
 
RNase inhibitor (Cat No.: N8080119; Applied Biosystems, CA, USA). 
 
RNeasy mini kit (Cat No.: 74106; Qiagen, Hilden, Germany). 
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Sorenson‟s Buffer pH 10.5 (prepared in the laboratory according to standard protocol; see 
Appendix I). 
- Glycine (Cat No.: 2139410; AnalaR Laboratories, Poole, England), 
- NaCl (Cat No.: AB006404.500; Merck, Midrand, South Africa), 
- NaOH (Cat No.: 10252; AnalaR Laboratories, Poole, England). 
 
TRI Reagent (Cat No.: 93289; Sigma, Manheim, Germany). 
 
Trypan blue (Cat No.: T93595; Sigma, Stanheim, Germany). 
 
Trypsin (Cat No.: 17-161F, Lonza, MD, USA) (See Appendix I for constituents). 
 
TURBO DNA-free kit (Cat No.: 1907; Ambion, Applied Biosystems, CA, USA). 
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1.2. Ex vivo experiment reagents 
125I-labeled rat insulin RIA kit (Cat No.: RI-13K; Linco research, St Charles, MO). 
 
26 gauge cannula catheter (Cat No.: NM126; Neotec Medical Industries, Singapore). 
 
BD OptEIA™ Rat TNF-alpha ELISA kit (Cat No.: 560479; BD Biosciences, Woodmead, 
South Africa). 
 
Collagenase P type I from Clostridium histolyticum (C0130; Sigma, Stanheim, Germany). 
 
Dihydrofluorescein diacetate (DAF) (Cat No.: 292648; Sigma, Stanheim, Germany). 
 
Geneticin (Cat No.: 11464990; Roche Diagnostics, IN, USA). 
 
Hanks Balanced Salt Solution (HBSS) (Cat No.: 14025; GIBCO, Invitrogen, Auckland, New 
Zealand). 
 
Histopaque (1.119 g/L) (Cat No.: 11191; Sigma, Stanheim, Germany). 
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Krebs-Ringer bicarbonate HEPES buffer (KRBH) (prepared in the laboratory according to 
standard protocol; see Appendix I). 
- NaCl (Cat No.: S5886; Sigma, Stanheim, Germany),      
- NaHCO3 (Cat No.: S3817; Sigma, Stanheim, Germany),     
- KCl (Cat No.: P5405; Sigma, Stanheim, Germany),     
- MgCl2 (Cat No.: M4880; Sigma, Stanheim, Germany),  
- CaCl2 (Cat No.: C5670; Sigma, Stanheim, Germany), 
- Bovine serum albumin (BSA) (Cat No.: A4919; Sigma, Stanheim, Germany), 
- 10 mM HEPES Buffer (Cat No.: 3344; Highveld Biological, Gauteng, South Africa). 
 
L-Glutamine (Cat No.: G8540; Sigma, Stanheim, Germany). 
 
Lipopolysaccharides from E.coli (LPS) (Cat No.: L6529; Sigma, Stanheim, Germany). 
 
Penicilin- streptomycin mixture (Cat No.: 17602; Lonza, MD, USA) 
 
RPMI 1640 Medium (Cat No.: 12-702F; Lonza, MD, USA). 
 
Sodium pentobarbital euthanase (Bayer Pty. Ltd., Animal Health Division, Isando, South 
Africa). 
 
Vacutainer® Ethylenediaminetetraacetic acid (EDTA) blood collection tubes (Cat No.: 
368861; BD Biosciences, Woodmead, South Africa). 
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2. Equipment 
2100 PCR Expert Software (Applied Biosystems, CA, USA). 
 
2720 Thermal cycler (Applied Biosystems, CA, USA). 
 
7500 RT PCR System (Applied Biosystems, CA, USA). 
 
ELX800 absorbance microplate reader (Bio Tek Instruments Inc; Friedrichshall, Germany). 
 
FACSCaliber™ (BD Biosciences, MD, USA). 
 
FLX800 fluorescence microplate reader (Bio Tek Instruments Inc.; Friedrichshall, 
Germany). 
 
Nanodrop ND-1000 spectrophotometer (Nanodrop, Thermo Scientific; DE, USA). 
 
Qiagen TissueLyser (Retsch Technology; Haan, Germany). 
 
3. Software packages 
7500 System Software v.1.4.0 (Applied Biosystems; CA, USA). 
 
Gen5 v.1.05 (BioTek Instruments Inc.; Friedrichshall, Germany). 
 
GraphPad Prism v.5.01 (GraphPad Software Inc.; CA, USA). 
 
WinMDI v.2.8 (Purdue University; IN, USA). 
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METHODOLOGY 
 
1. Source and preparation of Athrixia phylicoides extract 
A. phylicoides fine twigs and leaves, harvested in June 2005 in the Bushbuckridge area 
(Limpopo, South Africa), was identified by the South African National Botanical Institute 
(SANBI) and supplied by Prof Jana Olivier, University of South Africa. A freeze-dried 
aqueous extract of twigs and leaves of A. phylicoides (ARC401) was prepared on a pilot-
scale by Dr Dalene De Beer, Nietvoorbij, Agricultural Research Council of South Africa. 
The extract was prepared by boiling dried fine twigs and leaves in five batches of 1.4 kg/20 
L water for 10 minutes. After filtration the extract was concentrated using reverse osmosis 
and freeze-dried. The batch of dry extract was stored in the dark, under vacuum 
desiccation, at room temperature (20-24°C). 
 
1.1. Preparation of extract for in vitro and ex vivo assays 
Fresh solutions of the extract were reconstituted in cell culture tested water prior to each 
assay at a stock concentration of 1 mg/ml. The extract solution was sterile filtered by 
passing the solution through a sterile, low affinity 0.22 μm syringe driven filter unit. The 
sterile 1 mg/ml stock was diluted to the required assay concentrations in  base DMEM 
(without phenol red, pyruvate, L-glutamine and glucose) supplemented with 8 mM D-
glucose, 3.7 g/L NaHCO3 and 0.1% BSA.  
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2. In vitro experimental procedure 
2.1. Source and storage of cell lines 
Cryo-vials containing C2C12, Chang or 3T3-L1 cells, originally obtained from the American 
Type Culture Collection, were cryo-preserved in freshly prepared freezing medium 
containing cryo-protectant (7% DMSO) in the vapour phase of a liquid nitrogen tank.  
 
2.2. C2C12 cell line 
2.2.1. Thawing and counting of C2C12 cells 
A vial of C2C12 cells was removed from the nitrogen tank and thawed in a circulating 
water bath at 37 C with gentle agitation until only a very small piece of ice was left. The 
cell suspension in the vial was immediately aspirated using a 3 ml disposable Pasteur 
pipette and dispensed into 10 ml of fresh, warm DMEM supplemented with 10% FCS. To 
remove DMSO, the cell suspension was centrifuged at 800 x g for 5 minutes. The 
supernatant was discarded and the cells re-suspended in 10 ml fresh DMEM 
supplemented with 10% FCS. Cell concentration and viability was determined using a 
haemocytometer (figure 9).  
 
 
Figure 9. Haemocytometer chamber (a) and a 1 mm2 grid within the chamber (b) (PK 
Group standard protocol, 2004).  
a 
b 
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2.2.1.1. Cell viability 
Cell viability was determined by staining a 100 μl sample of the cell suspension with 100 μl 
of 0.4% trypan blue in DPBS solution in a 1.5 ml tube. A 10 μl sample of the stained cell 
suspension was pipetted under the coverslip of the two chambers of the haemocytometer. 
The number of cells in three 1 mm2 grids per chamber of the haemocytometer were 
counted and the average of the six counts was used to determine the total number of cells 
per milliliter. The membranes of viable cells exclude the blue trypan dye, and damaged or 
dead cells take up the stain. The number of viable cells was calculated by deducting the 
blue stained, non-viable cells from the total number of cells. Only cells with a viability of 
greater than 85% were used. 
 
C2C12 cells were seeded at 2 500 cells/cm2 into a 75 cm2 cell culture flask in 18 ml DMEM 
supplemented with 10% FCS and were incubated at 37 C in humidified air with 5% CO2 
until the following day. 
 
2.2.2. Sub-culture of C2C12 cells 
Cells were refreshed with DMEM supplemented with 10% FCS the following day and two 
days later were sub cultured into three 75 cm2 culture flasks at 2 500 cells/cm2 in order to 
obtain sufficient cells for each experiment. C2C12 cells are known to differentiate rapidly 
and form contractile myotubes that produce characteristic muscle proteins and myofibrils. 
During sub-culture, cells were not allowed to become confluent (i.e. less than 70% 
confluence) as this depletes the myocytic population. In order to loosen cells from the flask 
culture surface, all media was aspirated and cells were washed with 8 ml warm (37°C) 
DPBS and incubated for 7 minutes in 2 ml 0.25% Trypsin-versene at 37 C in humidified air 
with 5% CO2. Trypsinisation was stopped with the addition of 8 ml fresh DMEM 
supplemented with 10% FCS. A 100 μl sample of the cell suspension was counted and the 
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three flasks seeded at 2 500 cells/cm2. Two of the sub cultured flasks were used to seed 
assay multi-well plates or flasks and the third was sub cultured for further experiments. For 
this experiment C2C12 cells were sub cultured and assayed up to a passage number of 
19. Thereafter, a new vial of cells was thawed as described above as required. C2C12 
cells were seeded at 15 625 cells/cm2 for assay purposes into multi-well plates as 
described in the experimental procedure of each assay.  
 
2.2.3. Differentiation of C2C12 cells 
Differentiation of C2C12 cells was achieved by refreshing media with DMEM 
supplemented with 2% HS as opposed to the FCS added in normal cell culture. Since 
horse serum contains less growth factors than fetal calf serum, proliferation was reduced 
and myotubule formation was initiated. Cells were differentiated three days after being 
seeded into the assay plates/flasks. Differentiated C2C12 cells were characterised by a 
distinct change in morphology; from single, flat, poly-glonal shaped cells to spindle shaped 
myocytes and multi-nucleate, densely packed myotubules. The evening prior to the 
respective assay, cells were serum starved by replacing the media with DMEM 
supplemented with 0.5% HS. Assays were performed on the fifth day after seeding. 
 
2.3. Chang cell line 
2.3.1. Thawing of Chang cells 
Chang cells were thawed and the cells in suspension were immediately aspirated using a 
3 ml disposable Pasteur pipette and dispensed into 10 ml of fresh, EMEM supplemented 
with 10% FCS. Cell density and viability was determined as described in section 2.2.1. and 
viable Chang cells were seeded at 3 000 cells/cm2 into a 75 cm2 cell culture flask. The 
flask, with a total media volume of 18 ml, was incubated at 37 C in humidified air with 5% 
CO2 until the following day. 
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2.3.2. Sub-culture of Chang cells 
Chang cells were refreshed with EMEM supplemented with 10% FCS the following day. 
Two days later the cells were sub cultured into three 75 cm2 culture flasks at 3 000 
cells/cm2 in order to obtain sufficient cells for each experiment. Two of the sub cultured 
flasks were used to seed assay plates and the third was sub cultured for further 
experiments. In this study cells were sub cultured and assayed up to a passage number of 
19. In order to avoid contact inhibition, cultures were not allowed to become confluent. 
After 19 passages, a new vial of cells was thawed as required. Chang cells were seeded 
at 18 750 cells/cm2 for assay purposes into multi-well plates or flasks as described in the 
experimental procedure of each assay. The evening prior to the respective assay, cells 
were serum starved by replacing the media with EMEM supplemented with 0.5% FCS. 
Assays were performed on the fifth day after seeding. 
 
2.4. 3T3-L1 cell line 
2.4.1. Thawing of 3T3-L1 cells 
3T3-L1 cells are embryogenic pre-adipocytes developed through clonal isolation. As 
described for C2C12 cells above, 3T3-L1 cells were thawed and the cells in suspension 
were immediately aspirated using a 3 ml disposable Pasteur pipette and dispensed into 10 
ml of fresh, warm DMEM supplemented with 10% FCS. Cell density and viability was 
determined as described in section 2.2.1. and viable 3T3-L1 cells were seeded at 2 000 
cells/cm2 into a 75 cm2 cell culture flask. The flask, with a total media volume of 18 ml, was 
incubated at 37 C in humidified air with 5% CO2 until the following day. 
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2.4.2. Sub-culture of 3T3-L1 cells 
Seeded cells were refreshed with DMEM supplemented with 10% FCS the following day 
and two days later were sub cultured into three 75 cm2 culture flasks at 2 000 cells/cm2 in 
order to obtain sufficient cells for each experiment. Two of the sub cultured flasks were 
used to seed assay plates and the third was sub cultured for further experiments. In this 
study, 3T3-L1 cells were sub cultured and assayed up to a passage number of 19. 
Thereafter, a new vial of cells was thawed as required. 3T3-L1 cells were seeded at 12 
500 cells/cm2 for assay purposes into multi-well plates as described in the experimental 
procedure of each assay.  
 
2.4.3. Differentiation of 3T3-L1 cells 
To induce the adipocyte phenotype, 3T3-L1 cells were refreshed prior to reaching 
confluence (on day three) with adipogenic media (DMEM with 10% FCS was 
supplemented with 16 μM insulin, 0.6 μM dexamethasone and 0.1 mM IBMX). The 
transition from fibroblastic, progenitor mesenchymal cells to rounded, fully functional fat-
producing adipocytes requires two cell divisions in the adipogenic media, thus cells were 
refreshed for a further three days with the supplemented, adipogenic media. 3T3-L1 cells 
were then cultured in normal DMEM supplemented with 10% FCS for two days. The 
evening prior to the respective assay, cells were serum starved by replacing the media 
with DMEM supplemented with 0.5% FCS. Assays on 3T3-L1 cells were performed on the 
eighth day after seeding. 
 
2.5. Glucose Uptake Determination – Glucose oxidase fluorimetric method (method 
modified from Van de Venter et al., 2008) 
Cells (C2C12, Chang and 3T3-L1) were seeded into 24 well culture plates and were 
maintained as described in section 2.1 at 37 C in humidified air with 5% CO2 until the day 
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of the experiment (i.e. day five for C2C12 and Chang cells and day eight for 3T3 cells). 
 
On the day of the experiment, cells were rinsed with DPBS in order to remove leftover 
medium and glucose. Cells were then serum and glucose starved in DPBS for 30 minutes 
at 37 C in humidified air with 5% CO2 as this pre-sensitizes the cells. DPBS was aspirated 
and DMEM containing 8 mM glucose and 0.1% BSA was added to each well and, 
according to the plate layout (figure 10), either insulin (1.0 μM), metformin (1.0 μM), 
vehicle control (cell culture tested water) or ARC401 extract (0.025, 0.05, 0.1 μg/μl) was 
added. C2C12 cells were incubated for one hour, and Chang and 3T3 cells for three hours 
at 37ºC in humidified air with 5% CO2. 
 
1 2 3 4 5 6
A Insulin Metformin Control
B Insulin Metformin Control
C Insulin Metformin Control
D Insulin Metformin Control
Extract 
0.025 
µg/µl
Extract 
0.05 
µg/µl
Extract 
0.1 µg/µl
Extract 
0.1 µg/µl
Extract 
0.05 
µg/µl
Extract 
0.025 
µg/µl
Extract 
0.05 
µg/µl
Extract 
0.025 
µg/µl
Extract 
0.1 µg/µl
Extract 
0.1 µg/µl
Extract 
0.05 
µg/µl
Extract 
0.025 
µg/µl
 
 
Figure 10. Glucose uptake plate layout 
 
2.5.1. Fluorimetric glucose concentration determination in the media 
Glucose concentration of the media remaining in each well was determined by a 
fluorimetric glucose oxidase method (Biovision Glucose Uptake Assay Kit) following one or 
three hours incubation. A 4 μl medium sample was removed from each well and was 
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diluted 1 in 100 in ddH2O. Ten microlitres of the diluted sample was transferred to a 384 
well plate and 10 μl of kit reaction mix was added. The plate was incubated for 30 minutes 
at 37°C in the dark. The resulting reaction produced a pink solution which was 
fluorimetrically measured (Ex/Em 530/590) on a BioTek Flx800 plate reader. A glucose 
standard curve (supplied in the kit) was prepared for each plate read. The actual glucose 
concentration (μg/well) was calculated by plotting the fluorescent measurement of each 
sample on the standard curve using Gen5 software v.1.05. A blank reading was obtained 
from an empty well and subtracted from each glucose value. 
 
2.6. Glucose oxidation and glycogen content assays (methods modified from Gray 
and Flatt, 1998, and Huijing, 1970 respectively) 
Cells (C2C12, Chang and 3T3-L1) were seeded into three six well culture plates and were 
maintained at 37 C in humidified air with 5% CO2 until the day of the experiment (i.e. day 
five for C2C12 and Chang cells and day nine for 3T3 cells). 
 
On the day of the experiment, cells were rinsed with DPBS in order to remove leftover 
medium and glucose. Cells were then serum and glucose starved in DPBS for 30 minutes 
at 37 C in humidified air with 5% CO2. DPBS was aspirated and DMEM containing 8 mM 
glucose, 0.1% BSA and 0.5 μCi of glucose-D-[14C (U)] was added to each well. According 
to the plate layout (figure 11), either insulin (1.0 μM), metformin (1.0 μM), vehicle control 
(water) or extract (0.025, 0.05, 0.1 μg/μl) was added. 
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Extract
0.025 µg/µl
Extract
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Extract
0.10 µg/µl
ARC401 
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ARC401 
μ μ
ARC401 
0.1μ μ
 
 
Figure 11. Glucose oxidation assay and glycogen content determination plate layout 
 
2.6.1. 14C glucose oxidation assay (method adapted from Gray and Flatt, 1998) 
For this assay the sterile 1 mg/ml ARC401 stock was diluted in DMEM with phenol red to 
eliminate cell samples that may be compromised due to NaOH leakage from the filter 
paper used (as described below). Filter paper (Whatman no.1) moistened with 0.1 M 
NaOH was cut into well-size discs and placed over each well to trap 14C released by cells 
during glucose oxidation. C2C12 cells were incubated for one hour, and Chang and 3T3 
cells for three hours at 37ºC in humidified air with 5% CO2. The respective filter paper 
discs were removed and placed in scintillation vials with 1 ml ddH2O and 5 ml Ultima Gold 
liquid scintillation fluid. Samples were equilibrated overnight in the 2200CA Tri-carb Series 
liquid scintillation and cpm and dpm values measured the following day. Each sample was 
read for 1 minute. An average of two cpm and two dpm values were used per sample. 
Sample readings were normalised according to a standard curve for radioactive carbon 
(14C) that is installed in the 2200CA Tri-carb system.  
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2.6.2. Glycogen content determination (method adapted from Huijing, 1970) 
The cells were rinsed with warm (37°C) DPBS and trypsinised (0.5 ml 0.25% trypsin-
versene per well for 2 minutes at 37 C in humidified air with 5% CO2). Trypsinisation was 
stopped using ice cold DPBS. The cell suspension was counted using a haemocytometer 
(as described in section 2.1) and 1 x 106 cells were removed and centrifuged (800 x g for 5 
minutes at 4°C). The resultant pellet was resuspended in 200 μl ddH2O. The cell 
suspension was homogenized using a Qiagen TissueLyser (20/s for 2 minutes) and then 
boiled for 5 minutes to inactivate glycogen degrading enzymes such as phospho-
glucomutase and glycogen phosphorylase. The boiled samples were spun at 13 000 x g 
for 5 minutes and 50 μl of the supernatant was transferred to a 96 well plate and glycogen 
content was determined using a colourimetric glycogen assay kit from BioVision. To the 50 
μl supernatant sample, 2 μl of hydrolysis enzyme mix (provided in the kit) was added and 
the samples incubated at room temperature in the dark for 30 minutes. This was also done 
for the standards which were provided in the kit. Fifty microlitres of kit reaction mix was 
added to each sample and to the standards. Plates were incubated at room temperature 
for 30 minutes. The resulting pink solution was colourimetrically measured (absorbance 
was read at 577 nm on a BioTek® ELX 800 plate reader). The actual glycogen content was 
calculated by plotting the absorbance measurement of each sample on the standard 
curve. Results were normalised per million cells. Three independent experiments with 
three replicates per extract concentration and control were performed per cell line. 
 
2.7. Protein determination assay (method modified from Bradford, 1976) 
Protein determinations were performed for the assessment of radio-labeled deoxy-glucose 
uptake using the Bradford method according to the manufacturer‟s instructions (Bradford 
Biorad Assay, Biorad Laboratories, USA). A 5 l sample of lysed cells from each well/flask 
or bovine serum albumin (BSA) standards (supplied with the kit) was added to wells of a 
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96-well plate, followed by 250 µl of Bradford reagent. Plates were incubated in the dark for 
10 minutes and absorbance was read at 570 nm on a BioTek® ELX 800 plate reader. The 
actual protein concentration was calculated by plotting the absorbance measurement of 
each sample on the BSA standard curve. 
 
2.8. Chang cell MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) 
cytotoxicity assay (method modified from Mossman, 1983) 
Chang cells were seeded into 96 well culture plates and were maintained at 37 C in 
humidified air with 5% CO2 until the day of the experiment (i.e. day five). 
 
On the day of the experiment, cells were rinsed with DPBS in order to remove leftover 
medium and glucose. Cells were then serum and glucose starved in DPBS for 30 minutes 
at 37 C in humidified air with 5% CO2. DPBS was aspirated and DMEM containing 8 mM 
glucose and 0.1% BSA was added to each well, as well as vehicle control (water) and 
ARC401 extract at increasing concentrations (0.0125, 0.025, 0.05, 0.1, 1.0 µg/µl) 
according to the plate layout (figure 12). 
 
1 2 3 4 5 6 7 8 9 10 11 12
A Blank Blank Blank Blank Blank Blank Blank Blank Blank Blank Blank Blank
B Blank Vehicle 0.0125 µg/µl 0.025 µg/µl 0.05 µg/µl 0.1 µg/µl 1 µg/µl Blank Blank Blank Blank Blank
C Blank Vehicle 0.0125 µg/µl 0.025 µg/µl 0.05 µg/µl 0.1 µg/µl 1 µg/µl Blank Blank Blank Blank Blank
D Blank Vehicle 0.0125 µg/µl 0.025 µg/µl 0.05 µg/µl 0.1 µg/µl 1 µg/µl Blank Blank Blank Blank Blank
E Blank Vehicle 0.0125 µg/µl 0.025 µg/µl 0.05 µg/µl 0.1 µg/µl 1 µg/µl Blank Blank Blank Blank Blank
F Blank Vehicle 0.0125 µg/µl 0.025 µg/µl 0.05 µg/µl 0.1 µg/µl 1 µg/µl Blank Blank Blank Blank Blank
G Blank Vehicle 0.0125 µg/µl 0.025 µg/µl 0.05 µg/µl 0.1 µg/µl 1 µg/µl Blank Blank Blank Blank Blank
H Blank Blank Blank Blank Blank Blank Blank Blank Blank Blank Blank Blank
 
 
Figure 12. MTT cytotoxicity plate layout 
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The plates were incubated at 37 C in humidified air with 5% CO2 for 24 hours. All media 
was aspirated and 200 µl of fresh DMEM containing 8 mM glucose and 0.1% BSA (without 
phenol red) as well as 50 µl MTT solution (2 mg/ml DPBS) was added to each well and 
plates incubated for one hour. Once incorporated into the cells, the tetrazolium bromide is 
reduced in active mitochondria by mitochondrial dehydrogenase to formazan crystals. The 
non-solubilised formazan crystals formed over the one hour incubation period were 
dissolved in 200 µl DMSO and 25 µl Sorensen‟s glycine buffer pH 10.5. The resulting 
purple formazan solution was colourimetrically measured (absorbance was read at 570 nm 
on a BioTek® ELX 800 plate reader). Samples of ARC401 at the various concentrations 
tested were dissolved in media without phenol red and the absorbance read at 570 nm. To 
eliminate non-specific reaction between the extract, at the given concentrations, and the 
MTT solution, the optical density of extract dissolved in base DMEM containing 8 mM 
glucose and 0.1% BSA (without phenol red) as well as MTT solution was measured. 
These values were subtracted from the respective optical density of the samples per 
concentration tested. Three independent experiments with six replicates per extract 
concentration and control were performed. 
 
2.9. Ribonucleic acid (RNA) extraction, complementary DNA synthesis (cDNA) and 
real-time polymerase chain reaction 
Cells (C2C12, Chang and 3T3-L1) were seeded into four 75 cm2 flasks and were 
maintained at 37 C in humidified air with 5% CO2 until the day of the experiment (i.e. day 
five for C2C12 and Chang cells and day nine for 3T3 cells). 
 
On the day of the experiment, cells were rinsed with DPBS in order to remove leftover 
medium and glucose. Cells were then serum and glucose starved in DPBS for 30 minutes 
at 37 C in humidified air with 5% CO2. DPBS was aspirated and DMEM containing 8 mM 
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glucose and 0.1% BSA was added to each of the five flasks. To flask A, insulin was added 
to yield a final concentration of 1.0 μM, to flask B metformin (1.0 μM), to flask C vehicle 
control (water) and to flask D ARC401 extract (0.05 μg/μl). C2C12 cells were incubated for 
one hour, and Chang and 3T3-L1 cells for three hours at 37ºC in humidified air with 5% 
CO2. All media was then aspirated and cells trypsinised (2 ml 0.25% trysin-versene per 
flask). Trypsinisation was stopped with 8 ml ice cold DPBS per flask and the DPBS cell 
suspensions were frozen at -20ºC until the total number of experiments were completed 
(i.e. three independent experiments per cell line). 
 
2.9.1. RNA Extraction (method modified from Chomczynski and Sacchi, 1987) 
When all 36 cell samples were collected, the DPBS cell suspensions were spun down (800 
x g for 5 minutes at 4°C) and supernatants aspirated. The cell pellets were resuspended in 
1 ml TRI Reagent and transferred to 2 ml PCR tubes. The TRI reagent protects RNA by 
deactivating RNases which may still be active at 0°C. The samples were given abbreviated 
labels as shown in table in appendix II. 
 
All cell samples were homogenized using a Qiagen TissueLyser (20/s for 1 minute), rested 
on ice for 1 minute and homogenized again for 1 minute at 20 oscillations per second. The 
work surfaces used for all molecular work, as well as the equipment (e.g. pipettes) was 
wiped down with 70% ethanol and RNase free wipes. Cell samples were kept on ice 
throughout the RNA extraction, cDNA synthesis and reverse transcription-polymerase 
chain reaction (RT-PCR) processes in order to preserve RNA integrity. The homogenates 
were then spun at 12 000 x g for 10 minutes at 4°C. The supernatant, containing the RNA, 
was transferred to new 2 ml tubes.  Two hundred micro liters of chloroform was added to 
each tube and the tubes shaken for 3 minutes. Tubes were then centrifuged at 12 000 x g 
for 15 minutes at 4°C. The upper aqueous phase, containing the RNA was transferred to a 
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new 1.5 ml tube; with special precaution taken not to disturb the white interphase 
(containing DNA) or the pink/red organic phase (containing lipid and proteins) (figure 13). 
 
    
   Upper aqueous phase (RNA) 
   Intermediate phase (DNA) 
   Bottom organic phase (protein and lipid) 
 
Figure 13. Chloroform partitioning of RNA into aqueous supernatant by 
centrifugation. The upper aqueous phase containing the RNA was mixed with 500 μl 
isopropanol to precipitate RNA and incubated at -20°C overnight. 
 
2.9.1.1. RNA purification 
The following morning, tubes were removed from -20°C and centrifuged at 12 000 x g for 
20 minutes at 4°C. The supernatants were discarded and the RNA pellets washed twice in 
75% ethanol and allowed to partially dry. The partially-dried pellets were each re-dissolved 
in 100 μl RNase-free water. The suspensions were incubated at 55°C for 10 minutes on a 
heating block to promote solubilisation. RNA clean-up was done using a RNeasy mini kit 
from Qiagen. Three hundred and fifty microlitres of RLT lysis buffer (supplied in kit) and 
250 μl molecular grade absolute ethanol was added to each RNA solution. The entire 
volume of each sample was transferred to an RNeasy spin column placed in a 2 ml 
collection tube (supplied in kit). Samples were spun at 12 000 x g for 15 seconds at room 
temperature and the flow through discarded. Each RNA sample was retained in the 
respective column membrane. RPE buffer (supplied in kit) was diluted with four volumes of 
molecular grade absolute ethanol and 500 μl added to each spin column. The columns 
were spun for 15 seconds at 12 000 x g at room temperature. The flow through was 
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discarded and a further 500 μl RPE buffer added to each column before spinning for 
another 15 seconds at 12 000 x g at room temperature. Each column was transferred to a 
new 2 ml collection tube and spun at 12 000 x g for 1 minute at room temperature. The 
RNeasy spin columns were transferred to new 1.5 ml collection tubes and 40 μl RNase-
free water was added directly to each spin column membrane in order to elute RNA. 
Columns were allowed to stand for 1 minute and were then spun for 1 minute at 12 000 x g 
at room temperature. A further 40 μl RNase-free water was added directly to each spin 
column membrane and columns spun for 1 minute at 12 000 x g at room temperature. 
RNA yields were quantified using a Nanodrop ND-1000 spectrophotometer using 
absorption at 260 nm (A260). An A260 reading of 1 is equivalent to approximately 40 μg/ml 
of single-stranded RNA. An A260/A280 ratio of 2.0 indicates very pure RNA samples, with no 
protein contamination. An A260/A240 of 1.4 indicates very pure RNA samples, with no salt 
contamination. The instrument was blanked using 2 μl of RNase-free water and three 
measurements per sample were read. The Nanodrop spectrophotometer uses the Beer-
Lambert law to calculate UV absorbance by nucleic acid, where A260 = ECl (A = 
absorbance; E = extinction coefficient; C = concentration of nucleic acid; l = path length of 
the spectrophotometer cuvette). The extinction coefficient for RNA is 0.025 (mg/ml)-3cm-2 
and the path length of the spectrophotometer cuvette is typically 1 cm. The average of the 
three measurements was used in calculations performed in Excel (see table in appendix II) 
for DNase treatment and determining RNA integrity on an Agilent chip. 
 
2.9.1.2. Determining RNA Integrity 
Although the A260/A280 and the A260/A240 spectral ratios obtained from the Nanodrop 
indicate the protein and organic contamination of the RNA samples, true integrity and RNA 
quality is best determined by running RNA samples on an electrophoretic gel. The Agilent 
RNA 6000 Nano kit was used to determine RNA integrity. In the evaluation of both RNA 
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integrity and concentration, the Agilent 2100 Bioanalyser employs a combination of 
microfluidics, capillary electrophoresis and fluorescent dye that binds to nucleic acid. 
Nucleic acid fragments were separated based on their size as they were driven through 
the RNA chip electrophoretically. The RNA 6000 Nano dye, marker and filtered gel 
(supplied in the kit) were removed and allowed to equilibrate to room temperature. The 
Nano dye was vortexed for 10 seconds and spun down at 13 000 x g for 10 minutes at 
room temperature. One microlitre of Nano dye was added to the 65 μl filtered gel aliquot 
and the solution vortexed well and then spun at 13 000 x g for 10 minutes at room 
temperature. The RNA samples were denatured by placing samples on a heating block set 
at 70°C for 2 minutes. Electrodes on the Agilent Bioanalyser were cleaned and 
decontaminated using 350 μl of RNase-free water and 350 μl RNaseZap respectively. Gel-
dye mix, Nano marker (to confirm electrophoretic drive), RNA ladder and samples were 
loaded into the respective wells of the Agilent chip and the chip vortexed for 1 minute at 1 
159 x g. The RNA ladder was used as a reference standard and was composed of six 
RNAs ranging 25 – 500 ng/μl. The chip was read using 2100 Expert Software within 5 
minutes of preparation. Size and mass information was determined by the fluorescence of 
RNA molecules as they move through the channels of the chip.  The 2100 Expert Software 
compared the peak areas of the RNA samples to the combined area of the six RNA ladder 
peaks in order to determine RNA concentration. The software generated both a gel-like 
image and an electropherogram. The ratio of the two major ribosomal RNA species (i.e. 
18S and 28S; 1:2) was used to determine potential degradation of RNA (figure 14). A RNA 
integrity number (RIN) of 9.2 was considered good (intact, non-degraded total RNA) and a 
RIN of less than six was considered poor (partially degraded total RNA). 
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a.  
b.  
 
Figure 14. Electropherogram. Showing the characteristic signature of a high quality total 
RNA (100 ng) sample (a) and low quality total RNA sample (100 ng) (b). 
 
2.9.1.3. DNase Treatment 
A 20 μg sample of RNA was made up to 42 μl with RNase-free water according to the 
table in appendix II. Forty two micro litres of samples that had a total RNA content of less 
than 20 μg were used as required. 
 
To the diluted RNA, 5 μl of DNase buffer and 1.5 μl of Turbo DNase (as provided in the 
TURBO DNA-free kit from Ambion) was added and the mix incubated for 45 minutes at 
37°C. An additional 1.5 μl of Turbo DNase was added to each sample with further 45 
minutes incubation at 37°C. To stop the reaction, DNase inactivation reagent (provided in 
the kit) was added to the samples (10 μl per sample). Samples were centrifuged at 10 000 
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x g for 1.5 minutes and the supernatant (RNA) was transferred to a fresh 0.5 ml tube. 
DNA-free RNA concentrations were determined using a Nanodrop spectrophotometer as 
described in section 2.9.1.1. 
 
2.9.1.4. Reverse Transcription Complimentary DNA Synthesis 
Complementary DNA (cDNA) was synthesized from the RNA extracted from the C2C12, 
Chang and 3T3-L1 cells. The reaction was catalysed by the enzyme reverse transcriptase. 
Reverse transcriptase generates the complementary DNA based on the pairing of RNA 
base pairs (A, U, G, C) to their DNA compliments (T, A, C, G respectively). 
Deoxynucleoside triphosphates (dNTPs) (T, A, C, G) are added to the RNA samples with 
the reverse transcriptase enzyme. Random primers are also added to initiate the reverse 
transcriptase enzyme transcription of cDNA. High capacity cDNA kit components were 
thawed on ice. A 1 μg sample of RNA was made up to a total volume of 10 μl with RNase-
free water according to the table in appendix II in MicroAmp optical 96 well reaction plates. 
A negative (-ve) water control as well as two positive (+ve) controls (1 μg of Ambion 
mouse and 1 μg of Ambion human RNA control template) were prepared with the cell RNA 
samples. Mouse and human positive controls were used since C2C12 and 3T3-L1 cells 
are mouse-derived and Chang cells human-derived. All tubes were prepared in duplicate 
(i.e. a +ve and –ve reverse transcription control). 
 
 
 
 
 
 
 
52 | 
 
Two reverse transcription (RT) mastermixes were prepared according to kit instructions. 
The mastermixes were prepared as follows: 
Positive RT Mastermix (per reaction) – 2 μl RT buffer 
      0.8 μl dNTP mix 
      2 μl random primers 
      1 μl RNase inhibitor 
      3.2 μl nuclease-free water 
      1 μl reverse transcriptase 
 
Negative RT Mastermix (per reaction) – 2 μl RT buffer 
      0.8 μl dNTP mix 
2 μl random primers 
1 μl RNase inhibitor 
      4.2 μl nuclease-free water 
 
Mastermix was required for 38 samples (including controls) so 44 reactions were made per 
RT Mastermix. All reagents for the Mastermixes were provided in the High capacity cDNA 
kit. The respective Mastermixes were added to the 1 μg RNA samples (10 μl per sample) 
and the plate sealed. The 96 well plates were spun for 30 seconds at 3 000 x g to 
eliminate air bubbles. A 2720 Thermal cycler was used to amplify the RNA and was 
programmed as follows: 
Step 1 - 75°C (10 minutes) 
Step 2 - 37°C (120 minutes) 
Step 3 - 85°C (5 seconds) 
Step 4 - 4°C (∞) 
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The reaction volume was set to 20 μl, sample tubes were placed into the thermal cycler 
and the programme run. The first step in the thermal cycler allowed for the activation of the 
reverse transcriptase enzyme. Annealing of the dNTPs followed in the second step and 
extension of the sequence occured in the third. The fourth step cooled the newly 
synthesised cDNA to 4°C. Newly synthesized cDNA samples were removed within 30 
minutes after the completion of Step 4 and was then stored at -20°C. 
 
2.9.1.5. Testing cDNA 
cDNA was thawed on ice and work surfaces prepared by wiping with 70% ethanol. To 
confirm positive cycling prior to the identification and quantification of our desired 
sequences (i.e. those coding for insulin receptor, insulin receptor substrates 1 and 2, 
phosphoinositide-3-kinase and glucose transporter 4) the cDNA was tested using β-actin 
primers (forward and reverse). β-actin was used as it is a well known stably expressed 
gene that occurs in all tissue. The non-specific fluorescent dye SYBR green was used to 
confirm double stranded DNA (SYBR green intercalates with double stranded DNA). Two 
PCR reaction mixes were prepared per sample as follows: 
Mouse β-actin (Act B) Reaction Mix - 12.5 μl SYBR green 
      1 μl mouse Act B forward primer (10 μM) 
      1 μl mouse Act B reverse primer (10 μM) 
      9.5 μl nuclease-free water 
 
Human β-Actin (Act B) Reaction Mix - 12.5 μl SYBR green 
      1 μl human Act B forward primer (10 μM) 
      1 μl human Act B reverse primer (10 μM) 
      9.5 μl nuclease-free water 
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Since primers (and Syber green) were used to test the cDNA the dissociation step was 
added in the PCR programme run by 7500 RT-PCR System Sequence Detection Software 
version 1.4. 
 
According to the sample key (table in the appendix II) plate layout (figure 15), 1 μl of 
positive and negative cDNA samples and 24 μl of respective reaction mix was added to 
each well. The 96 well PCR plate was agitated for 5 minutes at 500 oscillations and spun 
down at 1 811 x g for 30 seconds and Real-Time PCR was run on a 7500 RT-PCR 
System. 
 
1 2 3 4 5 6 7 8 9 10 11 12
A 1+ 1- 9+ 9- 26+ 26- 34+ 34- 13+ 13- 23+ 23-
B 2+ 2- 10+ 10- 27+ 27- 35+ 35- 14+ 14- 24+ 24-
C 3+ 3- 11+ 11- 28+ 28- 36+ 36- 15+ 15- 25+ 25-
D 4+ 4- 12+ 12- 29+ 29- 37+ 37- 16+ 16- 39+ 39-
E 5+ 5- 30+ 30- 38+ 38- 17+ 17- 20+ 20-
F 6+ 6- 31+ 31- 20+ 20- 18+ 18-
G 7+ 7- 32+ 32- 21+ 21-
H 8+ 8- 33+ 33- 22+ 22-
 
Figure 15. cDNA PCR test plate layout. 
 
2.9.2. Real Time-PCR (RT-PCR) 
Polymerase chain reaction was used to amplify and quantify targeted DNA molecules. The 
DNA molecules (genes) of interest were insulin receptor (INSR), insulin receptor 
substrates 1 and 2 (IRS1 and IRS2), PI3K and glucose transporter 4 (GLUT4). Amplified 
DNA were detected and quantified as the reaction progressed in real time. Sequence-
specific probes for each of the genes of interest were used (rather than primers). Since 
55 | 
 
reporter probes offer higher specificity and enables quantification even in the presence of 
non-specific DNA amplification. DNA probes consist of oligonucleotides labeled with a 
fluorescent reporter which is cleaved once the probe hybridizes with its complimentary 
DNA target. The probe also has a quencher of fluorescence attached at the opposite end 
to the fluorescent reporter which prevents detection of fluorescence if the reporter is not 
cleaved. cDNA synthesized in section 2.9.1.4. was diluted 1:3 in nuclease-free water and 
kept on ice. Standard curves were prepared for the C2C12 and 3T3-L1 cells using 1 μg of 
mouse Ambion cDNA. Serial dilutions were made in nuclease-free water and 0.8 μl 
pipetted in duplicate into a 96 well PCR plate according to the plate layout below (figure 
16). Standard curves were similarly prepared for Chang cells using 1 μg of human Ambion 
cDNA. 
a. 
1 2 3 4 5 6 7 8 9 10 11 12
A 100 100
1+ 9+ 1+ 9+ 26+ 34+ 26+ 34+
B 10 10
2+ 10+ 2+ 10+ 27+ 35+ 27+ 35+
C 1 1
3+ 11+ 3+ 11+ 28+ 36+ 28+ 36+
D 0.1 0.1
4+ 12+ 4+ 12+ 29+ 37+ 29+ 37+
E 0.01 0.01
5+ 5+ 30+ 38+ 30+ 38+
F 0.001 0.001
6+ 6+ 31+ 20+ 31+ 20+
G 0.000 0.000
7+ 7+ 32+ 32+
H NTC NTC
8+ 8+ 33+ 33+
 
b. 
1 2 3 4 5 6 7 8 9 10 11 12
A 100 100
13+ 23+ 13+ 23+
B 10 10
14+ 24+ 14+ 24+
C 1 1
15+ 25+ 15+ 25+
D 0.1 0.1
16+ 39+ 16+ 39+
E 0.01 0.01
17+ 20+ 17+ 20+
F 0.001 0.001
18+ 18+
G 0.000 0.000
21+ 21+
H NTC NTC
22+ 22+
 
Figure 16. RT-PCR plate layouts for each of the six genes of interest. i.e. INSR, IRS1, 
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IRS2, PI3K and GLUT4; for C2C12 and 3T3-L1 cells (a) and Chang cells (b). 
A PCR reaction mix was prepared per gene of interest. The reaction mix contained the 
respective assay probe in a Taq polymerase assay master mix as follows per probe per 
sample: 
 
PCR Reaction Mix - 5 μl Master mix 
   0.5 μl Probe assay 
   3.7 μl nuclease-free water 
 
PCR reaction mix was required for 42 Chang cDNA samples (including standards). The 
diluted cDNA samples (0.8 μl) were pipetted into a 96 well PCR plate according to the 
plate layout above in duplicate. Similarly, 0.8 μl of the respective human and mouse cDNA 
Ambion was added to the 96 well plates. To each of the wells (including the standards), 
9.2 μl of PCR reaction mix was added. The 96 well plate/s were agitated for 5 minutes at 
500 oscillations per minute and centrifuged for 30 seconds at 1 811 x g. Real-Time PCR 
was run on a 7500 RT-PCR. Data was analysed using 7500 System Software v.1.4.0. 
Data was expressed relative to GAPDH and Actβ house-keeping genes. 
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3. Ex vivo experimental procedure 
Age matched, one year old, adult, male Wistar rats of similar body weight (250-300 g) 
were housed in a controlled environment (12 hour light/dark cycle at 22±2°C). Rats were 
maintained on a standardized laboratory diet according to the Medical Research Council 
Animal Unit standard operating procedures. The rats were anaethetised with 15 mg/kg 
sodium pentobarbital by intraperitoneal injection.  A mid-line abdominal incision (figure 
17a) was made and 24 ml of blood was collected (pooled from three rats) from the 
abdominal vena cava in EDTA tubes (figure 17b) for use in section 3.3. below. Pancreata 
were harvested for use in section 3.2. below. 
a.                    b.  
 
Figure 17. Mid-line abdominal incision (a) and blood collection (b) in a Wistar rat. 
(Diabetes Discovery Platform, 2010) 
 
3.1. Animal ethics 
All animal procedures were performed in accordance with the ethical code of conduct as 
prescribed by the latest South African Medical Research Council (MRC) “Guidelines on 
ethics for medical research: use of animals in research”. This study was approved by the 
Ethical Committee for Research on Animals (ECRA) (approval no. 09/09). 
4.5 cm 0.33 cm 
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3.2. Pancreatic islet and β-cell experimental procedure 
3.2.1. Isolation and culture of rat pancreatic islets (method adapted from Gotoh, 
Maki et al., 1987) 
The main pancreatic duct was identified by reflecting the duodenal loop, thereby exposing 
the main pancreatic duct and ampullae (figure 18). 
 
 
 
Figure 18. Reflection of the duodenal loop (D), exposing the pancreas (P) to allow 
for ductal cannullation (C). (Diabetes Discovery Platform)  
 
 
 
 
 
 
 
 
 
P 
D 
C 
0.63 cm 
59 | 
 
Rat pancreata were distended with 6 ml ice cold HBSS containing 1 mg/ml collagenase P 
via the main pancreatic duct using a 26 gauge neonatal canula under a stereo microscope.  
The pancreata were then carefully excised (figure 19) and placed in a sterile 50 ml tube on 
ice with a further 5 ml of collagenase P solution. Pancreata were carefully removed from 
along the gastrointestinal tract and the spleen. Visible excess fat was removed. 
 
 
 
Figure 19. Distended rat pancreas (P) semi-excised; attached to the spleen (SP), 
duodenum (D) and stomach (ST). (Diabetes Discovery Platform) 
 
Five pancreata were pooled to form one sample. The excised pancreata were digested at 
37ºC in a circulating water bath for 30 minutes with intermittent shaking.  The digestate 
was washed in 10 ml cold HBSS containing 0.1% BSA (HBSS/BSA), filtered through a 500 
μm nylon mesh and centrifuged at 600 x g for 15 minutes.  The pellet was again washed 
and centrifuged in 10 ml HBSS/BSA, the pellet was resuspended, layered onto a 
Histopaque gradient (15 ml Histopaque 1.119 g/l containing the digested pancreas tissue 
with 15 ml HBSS/BSA layered on top) and centrifuged at 800 x g for 20 minutes at 4°C 
with the brake off.  The islets were recovered from the HBSS/BSA layer, washed with 
HBSS and cultured for 24 hours in DMEM containing 5.5 mM glucose supplemented with 
10% FCS, 40 μg/ml geneticin, penicillin (100IU) and streptomycin (100 μg/ml) at 37ºC in 
D 
P 
ST 
SP 
1.4 cm 
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humidified air with 5% CO2. The following day approximately 1 000 islets were handpicked 
using a 100 μl pipette under a stereo microscope and cultured for 24 hours in two petri 
dishes in DMEM containing 5.5 mM glucose supplemented with 10% FCS, 40 μg/ml 
geneticin, penicillin (100IU) and streptomycin (100 μg/ml). To one of the petri dishes, 0.05 
μg/μl ARC401 was added to the culture medium. 
 
3.2.2. Glucose-stimulated insulin release assay (method modified from Henningsson 
et al., 2002) 
Cultured islets were washed and incubated for 30 minutes at 37ºC and 5% CO2 with 
KRBH containing 2.8 mM glucose.  The islets were equally separated into the wells of a 
six well plate incubated for two hours at 37ºC in humidified air and 5% CO2 with KRBH 
containing either 2.8 mM, 17 mM or 35 mM glucose according to the plate layout (figure 
20). 
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Figure 20. Isolated rat islet plate layout for the measurement of glucose-stimulated 
insulin secretion 
 
 
61 | 
 
Islets pre-exposed for 24 hours to ARC401 extract were seeded in row B and islets 
incubated without ARC401 for 24 hours were seeded into row A.  After 15 minutes and 
120 minutes, 200 μl KRBH was removed and the insulin concentration determined by 
radioimmunoassay (RIA) using a 125I-labeled rat insulin RIA kit. Unlabelled antigen (i.e. 
insulin in culture media) is added to fixed concentrations of labeled tracer antigen (125I-
labeled insulin) and antiserum (guinea pig anti-rat insulin). Unlabeled antigen competes 
with labeled tracer antigen for binding sites on the antibody; the amount of tracer bound to 
the antibody decreases with increasing concentrations of unlabeled antigen. The amount 
of unlabeled antigen is quantified relative to a standard curve which was set up using 
increasing concentrations (0.1 – 10 ng/ml) of standard unlabeled antigen. 
 
3.2.3. Flowcytometric determination of nitric oxide (NO) (method adapted from 
Strijdom et al., 2004) 
Immediately after the glucose-stimulated insulin release assay, a single cell suspension of 
β-cells was obtained by trypsinising the islets with 0.5 ml 0.25% trypsin-versene solution 
for 4 minutes, or until single cells could be seen under a stereo microscope. The single β-
cell suspensions were incubated with either 2.8 mM glucose or 35 mM glucose as well as 
10 mM DAF fluorescent nitric oxide (NO) label per well for two hours at 37ºC in humidified 
air and 5% CO2 (see plate layout, figure 21).  
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Figure 21. Isolated rat islet plate layout for the determination of nitric oxide 
produced by β-cells. 
 
β-cells were then washed with 5 ml per well warm (37°C) HBSS/BSA and intracellular 
fluorescence of the oxidized form of DAF, DAF-triazol (DAF-2T) was quantified by flow 
cytometry, using a 488 nm laser to interrogate the individual β-cells (events) and a 530 nm 
emission wavelength detector (FL1). WinMDI v. 2.8 was used to analyse data. Forward 
and side scatter data for 20 000 events was collected. β-cells were gated by their high side 
scatter properties and their mean fluorescence intensity calculated as a percentage of the 
control. 
 
3.3. Production of tumor necrosis factor alpha (TNF-α) by peripheral blood 
mononuclear cells (PMBCs) (method adapted from Wisman et al., 2008) 
3.3.1. Preparation of blood samples 
Blood collected from age matched, adult male Wistar rats in section 3. above was used to 
isolate peripheral blood mononuclear cells (PBMCs). Eight milliliters of whole blood was 
collected from anaethetised into Vacutainer® tubes containing 7.2 mg of EDTA to prevent 
clotting. The blood of three rats was pooled to yield a 24 ml sample. Each blood sample 
63 | 
 
was diluted 1:2 in DPBS and kept on ice. In order to retrieve the PBMCs from the whole 
blood, 24 ml of the diluted blood sample was layered over 12 ml Histopaque (1.119 g/l) in 
a 50 ml centrifuge tube. The tube was then centrifuged at 530 x g for 15 minutes at 4°C 
with the brake off. PBMCs (and platelets) were extracted from the second graduated layer 
between the Histopaque and the plasma layers (figure 22). 
 
                                                 
Figure 22. Histopaque gradient centrifugation and isolation of peripheral 
mononuclear cells (PBMCs) 
 
In order to remove platelets, a further 10 ml of cold DPBS was added to the PBMCs and 
the samples centrifuged at 130 x g for 15 minutes at 4°C. The supernatant was aspirated 
and the pellet re-suspended in DPBS followed by centrifugation at 130 x g for 15 minutes 
at 4°C. The supernatant was aspirated and the pellet re-suspended in RPMI 1640 
supplemented with 2 g/L sodium bicarbonate, 10% FCS, 2 mM L-glutamine, penicillin (100 
IU) and streptomycin (100 μg/ml). PBMC‟s were counted using a haemocytometer and 
seeded at 1 x 106 cells/ml in a 24 well cell culture plate with RPMI 1640 supplemented 
media with 0.05 μg/μl ARC401 extract and lipopolysaccharides (LPS) according to the 
Diluted blood 
Histopaque (1.119 g/L) 
Histopaque (1.119 g/L) 
Plasma 
PBMCs (and platelets) 
Red blood cells 
Centrifugation 
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plate layout below (figure 23). The plate was incubated for 24 hours at 37ºC with 
humidified air and 5% CO2. 
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Figure 23. PBMC plate layout. 
 
The next day contents of the wells were transferred to 2 ml microfuge tubes and a 100 μl 
sample per well was collected to determine cell viability as described in section 3.3.3. 
below. The remaining contents in the microfuge tubes were centrifuged at 10 000 x g for 
15 minutes. The supernatants were collected into 1.5 ml microfuge tubes and frozen at -
20°C for use in a sandwich ELISA assay to quantify TNF-α. One experiment with four 
replicates per treatment was performed. 
 
3.3.2. Enzyme-linked immune absorbent assay (ELISA) 
A BD Biosciences OptEIA sandwich enzyme-linked immune absorbent assay (ELISA) kit 
was used to quantify TNF-α produced by the PBMCs. Frozen culture medium 
supernatants were added to the ELISA plate (100 μl/well). The plates were pre-coated with 
anti-rat TNF-α monoclonal antibody, which binds TNF-α in the culture medium.  Standards 
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(provided in the kit) were also added to the respective wells. The plates were sealed and 
incubated at room temperature for 2 hours. The wells were then washed four times with 
300 μl/well wash buffer (supplied in the kit) and 100 μl/well detection antibody (biotinylated 
anti-rat TNF-α phage Fab antibody) was added. Plates were then sealed and incubated at 
room temperature for 1 hour. The washing step described above was repeated and 100 
μl/well enzyme working reagent (streptavidin-horseradish peroxidase conjugate with BSA) 
was added. Avidin-biotin  was used to amplify signal since numerous biotin molecules can 
be conjugated to the specific antibody (one molecule of avidin non-covalently binds four 
biotinylated proteins). The plate was resealed and incubated at room temperature for 30 
minutes. After incubation, the wash step was repeated and 100 μl/well 3, 3‟, 5, 5‟-
tetramethylbenzadine (TMB) One-step substrate reagent (provided in the kit) was added 
and plates incubated in the dark at room temperature for 30 minutes. The TMB reagent 
produces a blue color which was in direct proportion to the amount of TNF-α present. 
Thereafter, 50 μl/well of Stop solution (provided in the kit) was added to stop the reaction, 
changing the solution colour to yellow. The absorbance of the resultant yellow solution was 
read at 450 nm on a BioTek plate reader. 
 
3.3.3. Cell viability 
Peripheral blood mononuclear cell viability was determined as described in section 2.2.1.1. 
by staining the 100 μl sample obtained in section 3.3.1. above 100 μl of 0.4% Trypan blue 
in DPBS solution in a 1.5 ml tube. A 10 μl sample of the stained cell suspension was 
pipetted under the coverslip of the two chambers of the haemocytometer. The number of 
cells in three 1 mm2 grids per chamber of the haemocytometer were counted and the 
average of the six counts was used to determine the total number of viable cells per well. 
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4. Statistical analysis 
All in vitro work was done with three repeats in three independent experiments. Significant 
differences between groups were determined using the multivariate analysis of variance 
(ANOVA) statistical assessment. A one way ANOVA was used instead of a simple t-test in 
order to avoid false-positive type-I errors that may arise from multiple two-sample t-tests. A 
Dunnett‟s post hoc test was also performed if p<0.05, comparing the treatment group 
means to that of the vehicle control. Specific attention was given to correct sample size, 
controls and avoidance of type-II errors. Statistical significance was obtained when the p-
value was less than 0.05.  A non-parametric Spearman‟s correlation was performed on 
data in order to determine possible extract concentration related trends. Relative gene 
expression was analysed using fold change compared to the vehicle control samples. A 
1.5 fold change was regarded as meaningful. Statistical analysis was not performed on 
pancreatic islet and β-cell results as the experiment was not repeated. Nitric oxide 
production, as measured by diaminofluorescein diacetate triazol fluorescence, was 
analysed using fold change compared to the control group not pretreated with ARC401. 
Significant differences between groups compared to the negative control in the PBMC 
TNF-α quantification assay was analysed using ANOVA and a Dunnett‟s post hoc test was 
also performed. Graph Pad Prism v.5.01 was used for all statistical analyses. 
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CHAPTER 3 
RESULTS 
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1. Differentiation of C2C12 myoblasts and 3T3 pre-adipocytes into myocytes and 
adipocytes, respectively 
Since HS contains less growth factors than fetal calf serum, proliferation of C2C12 
myoblasts was arrested. Differentiation to myocytic phenotype with myotubule formation 
was initiated by substituting 10% fetal calf serum in the medium with 2% horse serum. 
Differentiated C2C12 cells are characterised by a distinct change in morphology; from 
single, flat, poly-glonal shaped cells (figure 24a) to spindle shaped myocytes and multi-
nucleate, densely packed myotubules which are similar to normal muscle fibres, with 
contractile ability (figure 24b). Fully differentiated C2C12 cells were characterized 
morphologically by the condensation of neighboring myocytes into myotubules.  
 
 
a.            b.  
 
Figure 24. Myocyte and myotubule formation in C2C12 cells.  
C2C12 myoblasts prior to differentiation on day two (arrow indicates single poly-glonal 
myoblast) (a) and spindle-shaped C2C12 myocytes with multi-nucleate, densely packed 
myotubules after differentiation on day five (arrows indicate condensed myotubules) (b) at 
400 x magnification. 
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To induce the adipocyte phenotype, 3T3-L1 cells were refreshed prior to reaching 
confluence with adipogenic media (DMEM with 10% FCS was supplemented with 16 μM 
insulin, 0.6 μM dexamethasone and 0.1 mM isobutylmethylxanthine). The transition from 
fibroblastic, progenitor mesenchymal cells (figure 25a) to rounded, fully functional fat-
producing adipocytes (figure 25b and c) required two cell divisions in the adipogenic 
media. Fully differentiated adipocytes were characterised morphologically with the 
observation of fat/lipid droplets in the cell cytoplasm. 
 
a.           b.  
c.  
                    
Figure 25. Adipocyte formation in 3T3-L1 fibroblasts. 
3T3-L1 fibroblasts prior to differentiation on day three (a) and 3T3-L1 adipocytes after 
differentiation on day six (b) at 200 x magnification (ZenBio Inc, 2010); 3T3-L1 adipocytes 
during differentiation on day four (c) with lipid stained in red with Oil RedO at 400 x 
magnification. Arrows indicate lipid accumulation. 
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2. Athrixia phylicoides aqueous extract (ARC401) and cellular glucose uptake 
The glucose oxidase fluorimetric was used to determine the amount of glucose taken up 
by C2C12, Chang and 3T3-L1 cells following acute exposure to ARC401 and positive 
controls. Chang and 3T3-L1 cells were acutely exposed for three hours to 1 μM insulin, 1 
μM metformin, water vehicle and increasing concentrations of ARC401 (0.025, 0.05 and 
0.1 μg/μl). C2C12 cells were acutely exposed for one hour. 
 
Measurement of glucose removed from the media by the cell lines showed that, compared 
to the water control, ARC401 significantly increased the amount of glucose taken up by 
C2C12 cells at 0.025, 0.05 and 0.1 μg/μl (183.4% ± 32.6, p<0.01; 228.3% ± 66.2, p<0.001; 
161.7% ± 8.5, p<0.05) (figure 26). In Chang cells ARC401 significantly increased the 
amount of glucose taken up at 0.05 and 0.1 μg/μl (134.5% ± 2.5, p<0.05; 130.9% ± 5.8, 
p<0.05) (figure 27). In 3T3-L1 cells ARC401 significantly increased the amount of glucose 
taken up at 0.025 and 0.05 μg/μl (143.5% ± 10.3, p<0.001; 134.7% ± 18.8, p<0.01) (figure 
28). In C2C12, Chang and 3T3-L1 cells the insulin (301.3% ± 12.3, p<0.001; 155.1% ± 
44.5, p<0.01; 188.0% ± 40.7, p<0.001) and metformin (206.8% ± 1.8, p<0.01; 171.4% ± 
44.3, p<0.01; 188.5% ± 13.4, p<0.001) (figures 26-28) positive controls significantly 
increased glucose taken up from the media. Insulin and maximal ARC401 glucose uptake 
stimulation was 1.9 and 1.7 fold higher in C2C12 myocytes compared to Chang cells, and 
1.6 fold higher in C2C12 cells compared to 3T3-L1 adipocytes. 
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Figure 26. Percentage glucose taken up from the media by C2C12 myocytes 
following acute exposure to ARC401 at increasing concentrations and controls 
(insulin, metformin and water vehicle). Results are mean values of three independent 
experiments + standard deviation. * p<0.05, ** p<0.01, *** p<0.001 compared to vehicle 
control. 
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Figure 27. Percentage glucose taken up from the media by Chang cells following 
acute exposure to ARC401 at increasing concentrations and controls (insulin, 
metformin and water vehicle). Results are mean values of three independent 
experiments + standard deviation. * p<0.05, ** p<0.01 compared to vehicle control. 
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Figure 28. Percentage glucose taken up from the media by 3T3-L1 adipocytes 
following acute exposure to ARC401 at increasing concentrations and controls 
(insulin, metformin and water vehicle). Results are mean values of three independent 
experiments + standard deviation. ** p<0.01, *** p<0.001 compared to vehicle control
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3. Glucose oxidation and glycogen content assays 
The effect of ARC401 on glucose utilization in C2C12, Chang and 3T3-L1 cells was 
assessed by measuring the amount of glucose stored as glycogen and the amount of 
glucose oxidized to CO2. Intracellular glycogen content was measured using a colorimetric 
assay kit in cells acutely exposed to increasing concentrations of ARC401 (0.025, 0.05 
and 0.1 μg/μl) as well as 1 μM insulin, 1 μM metformin, water vehicle. C2C12 myocytes 
were acutely exposed for one hour. Chang cells and 3T3-L1 adipocytes were acutely 
exposed for three hours. 
 
3.1. 14C-glucose oxidized to 14CO2 by C2C12, Chang and 3T3-L1 cells 
The oxidation of 14C-glucose to 14CO2 by C2C12 myocytes was significantly increased 
following acute exposure to ARC401 at 0.05 and 0.1 μg/μl (2806.3 fmol/1x10^6 cells ± 
751, p<0.05; 2919.3 fmol/1x10^6 cells ± 428, p<0.01). Acute exposure of C2C12 myocytes 
to ARC401 at 0.025 μg/μl had no effect on 14C-glucose oxidation to 14CO2. Positive 
controls, 1 μM insulin and 1 μM metformin, increased oxidation in of 14C-glucose to 14CO2 
in C2C12 myocytes. The increased oxidation induced by metformin was statistically 
significant (2905.9 fmol/1x10^6 cells ± 729.6, p<0.05) (figure 29). The oxidation of 14C-
glucose to 14CO2 by Chang cells was significantly increased following acute exposure to 
ARC401 at 0.05 and 0.1 μg/μl (3115.7 fmol/1x10^6 cells ± 743.6, p<0.05: 4476.7 
fmol/1x10^6 cells ± 1620, p<0.05); as seen in the C2C12 cells. Acute exposure of Chang 
cells to ARC401 at 0.025 μg/μl had no effect on 14C-glucose oxidation to 14CO2. Positive 
controls, 1 μM insulin and 1 μM metformin, increased oxidation of 14C-glucose to 14CO2 in 
Chang cells (figure 30). ARC401, at the concentrations tested, showed some inhibition of 
oxidation of 14C-glucose to 14CO2 by 3T3-L1 cells. Insulin and metformin positive controls 
had no effect on glucose oxidation in 3T3-L1 cells following acute exposure (figure 31).  
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Figure 29. 14C-glucose oxidized to 14CO2 by C2C12 myocytes during acute exposure 
to ARC401 at increasing concentrations and controls (insulin, metformin and water 
vehicle). Results are mean values of three independent experiments + standard deviation. 
* p<0.05, ** p<0.01 compared to vehicle control. 
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Figure 30. 14C-glucose oxidized to 14CO2 by Chang cells during acute exposure to 
ARC401 at increasing concentrations and controls (insulin, metformin and water 
vehicle). Results are mean values of three independent experiments + standard deviation. 
* p<0.05 compared to vehicle control. 
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Figure 31. 14C-glucose oxidized to 14CO2 by 3T3-L1 adipocytes during acute 
exposure to ARC401 at increasing concentrations and controls (insulin, metformin 
and water vehicle). Results are mean values of three independent experiments + 
standard deviation.  
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3.2. Glycogen content determination in C2C12 and Chang cells 
ARC401, only at the highest concentration tested (0.1 μg/μl), increased glycogen storage 
in C2C12 myocytes, although not significantly (figure 32). The 1 μM insulin positive control 
also non-significantly increased glycogen storage in the C2C12 myocytes, whereas 1 μM 
metformin control reduced the amount of glycogen stored. ARC401 significantly increased 
glycogen storage at all three concentrations tested in Chang cells (13.6 μg/1x10^6 cells ± 
0.7, p<0.05; 12.7 μg/1x10^6 cells ± 1.8, p<0.05; 12.7 μg/1x10^6 cells ± 1.6, p<0.05) (figure 
33). Both insulin and metformin postitive controls also significantly increased glycogen 
storage in the Chang cells (12.7 μg/1x10^6 cells ± 1.5, p<0.05; 13.3 μg/1x10^6 cells ± 4, 
p<0.01). The assay kit used in this study was not able to detect the amount of glycogen 
stored by the 3T3-L1 adipocytes. 
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Figure 32. Glycogen content of C2C12 myocytes following acute exposure to 
ARC401 at increasing concentrations and controls (insulin, metformin and water 
vehicle). Results are mean values of three independent experiments + standard deviation. 
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Figure 33. Glycogen content of Chang cells following acute exposure to ARC401 at 
increasing concentrations and controls (insulin, metformin and water vehicle). 
Results are mean values of three independent experiments + standard deviation. * p<0.05, 
** p<0.01 compared to vehicle control. 
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4. Chang cell MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) 
cytotoxicity assay 
Following chronic exposure (24 hours), the mitochondrial activity of Chang cells, as 
determined by the MTT assay, remained consistent and comparable with the water vehicle 
control at all concentrations of ARC401 tested except the highest (1 μg/μl) (0.28 nm ± 
0.03, p<0.01). At 1 μg/μl mitochondrial activity was significantly reduced when compared 
to the water vehicle control (figure 34). 
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Figure 34. MTT of Chang cells following chronic exposure to water vehicle control 
and ARC401 at increasing concentrations. Results are mean values of three 
independent experiments + standard deviation. ** p<0.01 compared to vehicle control. 
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5. RNA extraction, complementary DNA synthesis (cDNA) and real-time polymerase 
chain reaction 
The effect of ARC401 on insulin signalling gene expression in C2C12, Chang and 3T3-L1 
cells was assessed by extracting RNA from cells acutely exposed to ARC401 (0.05 μg/μl) 
as well as 1 μM insulin, 1 μM metformin, water vehicle. C2C12 myocytes were acutely 
exposed for one hour. Chang cells and 3T3-L1 adipocytes were acutely exposed for three 
hours. RNA was extracted using a Tri-reagent based method modified from Chomczynski 
and Sacchi (1987).  RNA was purified and DNase treated. Agilent RNA 6000 Nano kit was 
used to determine RNA integrity. The 2100 Expert Software compared the peak areas of 
the RNA samples to the combined area of the six RNA ladder peaks in order to determine 
RNA concentration. Complementary DNA (cDNA) was synthesized from the RNA 
extracted and mouse and human positive controls were used since C2C12 and 3T3-L1 
cells are mouse-derived and Chang cells human-derived. To confirm positive cycling prior 
to the identification and quantification of our desired sequences the cDNA was tested 
using β-actin primers (forward and reverse). Polymerase chain reaction was used to 
amplify and quantify targeted DNA molecules. The DNA molecules (genes) of interest 
were insulin receptor (INSR), insulin receptor substrates 1 and 2 (IRS1 and IRS2), PI3K 
and glucose transporter 4 (GLUT4). Amplified DNA were detected and quantified as the 
reaction progressed in real time. 
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5.1. Agilent bioanalyser one dimensional gels 
Samples obtained from C2C12 myocytes in the first two experiments (A1-A5 and B1-B5) 
showed distinct 28s and 18s bands. The 28s band of the samples obtained from the third 
experiments in C2C12 myocytes (C1-C5) was not as defined. Bands of the C5 sample 
were not clearly visible (figure 35). RNA extracted from Chang cells showed distinct and 
crisp 28s and 18s bands with the exception of sample F2, which was subsequently 
excluded from the rest of the PCR process (figure 36). RNA extracted from 3T3-L1 cells 
showed distinct 28s and 18s bands. Sample I2 showed lower intensity bands (figure 37). 
 
 
 
Figure 35. Agilent bioanalyser one dimensional gel of RNA extracted from C2C12 
myocytes following acute exposure to insulin (A1, B1, C1), metformin (A2, B2, C2) 
water vehicle control (A3, B3, C3) and ARC401 (A5, B5, C5).  
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Figure 36. Agilent bioanalyser one dimensional gel of RNA extracted from Chang 
cells following acute exposure to insulin (D1, E1, F1), metformin (D2, E2, F2) water 
vehicle control (D3, E3, F3) and ARC401 (D5, E5, F5).  
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Figure 37. Agilent bioanalyser one dimensional gel of RNA extracted from 3T3-L1 
adipocytes following acute exposure to insulin (G1, H1, I1), metformin (G2, H2, I2) 
water vehicle control (G3, H3, I3) and ARC401 (G5, H5, I5).  
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5.2. Dissociation curves of cDNA synthesized from RNA extracted from C2C12, 
Chang and 3T3-L1 cells acutely exposed to ARC401 
All cDNA samples showed positive cycling, with dissociation curve peaks for each cell line 
falling within a tight band (figure 38). In the Chang cells (figure 39), the positive human 
Ambion control peaked approximately 2°C before that of the samples, which were 
clustered together. The 3T3-L1 adipocyte peaks were also clustered together (figure 40). 
C2C12 myocytes peaked approximately 2°C below Chang cells and 3T3-L1 adipocytes 
(figure 41). 
 
 
 
Figure 38. Dissociation curve of cDNA extracted from C2C12 myocytes when probed 
with β-actin forward and reverse primers. 
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Figure 39. Dissociation curve of cDNA extracted from Chang cells when probed with 
β-actin forward and reverse primers. 
 
 
 
Figure 40. Dissociation curve of cDNA extracted from 3T3-L1 adipocytes when 
probed with β-actin forward and reverse primers. 
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Figure 41. Dissociation curve of cDNA extracted from C2C12 myocytes, Chang cells 
and 3T3-L1 adipocytes when probed with β-actin forward and reverse primers. 
C2C12 myocytes peak (purple arrow) approximately 2°C below Chang cells and 3T3-L1 
adipocytes (green arrow). 
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5.3. Insulin signalling gene expression 
Polymerase chain reaction was used to amplify and quantify targeted DNA molecules 
synthesized from C2C12 myocyte and Chang cell RNA. The DNA molecules (genes) of 
interest were INSR, IRS1, IRS2, PI3K and GLUT4. Genes of interest were expressed 
relative to two house-keeping genes actin-β and GAPDH). Amplified DNA were detected 
and quantified as the reaction progressed in real time. The probes used were not effective 
in 3T3-L1 cells. 
 
5.3.1. Insulin receptor (INSR) PCR assay 
ARC401 increased INSR expression 2.7 fold compared to the water vehicle control in 
C2C12 myocytes (figure 42). The insulin and metformin positive controls also increased 
INSR expression in the C2C12 myocytes 3 and 2.4 fold respectively. ARC401 had no 
effect on INSR expression in Chang cells (figure 43). The insulin positive control increased 
INSR expression and metformin had no effect on INSR expression in the Chang cells. 
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Figure 42. Relative expression of insulin receptor (INSR) of C2C12 myocytes 
following acute exposure to ARC401 controls (insulin, metformin and water vehicle). 
Results are the mean of two independent experiments + standard deviation. 
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Figure 43. Relative expression of insulin receptor (INSR) of Chang cells following 
acute exposure to ARC401 controls (insulin, metformin and water vehicle). Results 
are the mean of two independent experiments + standard deviation. 
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5.3.2. Insulin receptor substrate one (IRS1) PCR assay 
ARC401 had no effect on IRS1 expression in C2C12 myocytes (figure 44). The insulin and 
metformin positive controls each showed a 1.5 fold increase in IRS1 expression in the 
C2C12 cells. ARC401, as well as metformin, decreased IRS1 expression in Chang cells 
(figure 45). The insulin positive control had no effect on IRS1 expression in the Chang 
cells. 
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Figure 44. Relative expression of insulin receptor substrate one (IRS1) of C2C12 
myocytes following acute exposure to ARC401 controls (insulin, metformin and 
water vehicle). Results are the mean of two independent experiments + standard 
deviation. 
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Figure 45. Relative expression of insulin receptor substrate one (IRS1) of Chang 
cells following acute exposure to ARC401 controls (insulin, metformin and water 
vehicle). Results are the mean of two independent experiments + standard deviation. 
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5.3.3. Insulin receptor substrate two (IRS2) PCR assay 
ARC401 had no effect on IRS1 expression in C2C12 myocytes (figure 46). The insulin 
positive control showed a 1.7 fold increase in IRS2 expression. Metformin positive control 
had no effect in the C2C12 myocytes. ARC401, as well as metformin, had no effect on 
IRS2 expression in Chang cells (figure 47). The insulin positive control increased IRS2 
expression in the Chang cells. 
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Figure 46. Relative expression of insulin receptor substrate two (IRS2) of C2C12 
myocytes following acute exposure to ARC401 controls (insulin, metformin and 
water vehicle). Results are the mean of two independent experiments + standard 
deviation. 
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Figure 47. Relative expression of insulin receptor substrate one two (IRS2) of Chang 
cells following acute exposure to ARC401 controls (insulin, metformin and water 
vehicle). Results are the mean of two independent experiments + standard deviation. 
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5.3.4. Phosphoinositide-3-kinase (PI3K) PCR assay 
ARC401 had no effect on PI3K expression in C2C12 myocytes (figure 48). The insulin and 
metformin positive controls also had no effect on PI3K expression in C2C12 myocytes. 
ARC401, as well as positive controls insulin and metformin, had no effect on PI3K 
expression in Chang cells (figure 49). 
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Figure 48. Relative expression of phosphoinositide-3-kinase (PI3K) of C2C12 
myocytes following acute exposure to ARC401 controls (insulin, metformin and 
water vehicle). Results are the mean of two independent experiments + standard 
deviation. 
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Figure 49. Relative expression of phosphoinositide-3-kinase (PI3K) of Chang cells 
following acute exposure to ARC401 controls (insulin, metformin and water vehicle). 
Results are the mean of two independent experiments + standard deviation. 
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5.3.5. Glucose transporter 4 (GLUT4) PCR assay 
ARC401 increased GLUT4 expression 2 fold compared to the water vehicle control in 
C2C12 myocytes (figure 50). The insulin and metformin positive controls also increased 
GLUT4 expression in the C2C12 myocytes 1.4 and 1.9 fold respectively. 
 
0
1
2
3
4
5
Insulin Metformin Vehicle ARC401
R
e
la
ti
v
e
 e
x
p
re
s
s
io
n
 
Figure 50. Relative expression of glucose transporter 4 (GLUT4)  of C2C12 myocytes 
following acute exposure to ARC401 controls (insulin, metformin and water vehicle). 
Results are the mean of two independent experiments + standard deviation. 
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6. Pancreatic islet and β-cell assays 
Pancreata were isolated from adult, male Wistar rats and islets retrieved by histopaque 
centrifugation. The isolated islets were cultured overnight and a glucose-stimulated insulin 
release assay was performed the following day. Prior to the glucose-stimulated insulin 
release assay, individual islets of medium to large size (approximately 30-60 μm) were 
hand-picked under a stereo-microscope in order to obtain a more purified sample (figure 
51). Isolated islets were then trypsinised to retrieve individual β-cells, which were used in 
the flow cytometric determination of nitric oxide (as measured by diaminofluorescein-triazol 
fluorescence), in response to hyperglycaemia (figure 52). 
 
a.                  b.   
 
Figure 51. Isolated rat pancreatic islets (arrows) on the day of isolation at 200 x 
magnification (a) and after being hand-picked the day after isolation at 400 x 
magnification (b). 
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Figure 52. Diaminofluorescein-triazol (DAF-2T) fluorescence of a cluster of β-cells. 
Individual β-cells are indicated by the arrows. 
 
6.1. Glucose-stimulated insulin release assay 
Freshly isolated rat pancreatic islets were pre-exposed to ARC401 (0.05 μg/μl) and then 
acutely stimulated (120 minutes) with increasing glucose concentrations (2.8 mM, 17 mM 
and 35 mM). Insulin secreted into the medium was measured after 15 minutes and 120 
minutes of glucose stimulation. ARC401 reduced both first phase (15 min) and second 
phase (120 min) insulin response in β-cells by 0.9 fold at low glucose (2.8 mM) 
concentrations (figure 53). At higher glucose concentrations (17 mM and 35 mM), ARC401 
increased the first phase insulin response by 1.2 and 1.9 fold respectively. Similarly, 
ARC401 decreased second phase insulin response at 17 mM and 35 mM glucose 
concentrations by 0.7 and 0.6 fold respectively. 
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Figure 53. Insulin secretion at 15 and 120 minutes following glucose-stimulation in 
pancreatic islets pre-exposed to ARC401. Results are the mean + standard deviation of 
one experiment with two replicates.  
 
6.2. Flowcytometric determination of nitric oxide (NO) 
The single β-cell suspensions were acutely exposed to non-stimulatory (2.8 mM glucose) 
and hyper-stimulatory glucose (35 mM glucose) and incubated with 10 mM DAF 
fluorescent nitric oxide (NO). Intracellular fluorescence of the oxidized form of DAF, DAF-
triazol (DAF-2T) was quantified by flow cytometry. Β-cells were gated into region one (R1) 
due to their higher granularity (SSC-Height) and/or larger size (FSC-Height) (figure 54). 
The black population to the bottom left of figure 54 represents cellular debris, 
miscellaneous endothelial cells and other islet cells. High glucose concentration (35 mM) 
increased DAF-2T fluorescence (i.e. nitric oxide production) in β-cells 1.3 fold compared to 
β-cells incubated in KRBH containing 2.8 mM glucose (figure 55). ARC401 decreased 
DAF-2T fluorescence (i.e. nitric oxide production) in β-cells 0.5 fold compared to β-cells 
incubated in KRBH containing 2.8 mM glucose only (figure 56). ARC401 had no effect on 
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DAF-2T fluorescence (i.e. nitric oxide production) in β-cells compared to β-cells incubated 
in KRBH containing 35 mM glucose only (figure 57). 
 
Figure 54. Β-cell population gating on a forward scatter (FSC-Height) side scatter 
(SSC-Height) dot plot.  
 
 
Figure 55. Region one gated DAF-2T fluorescence in β-cells incubated in 2.8 mM 
(purple) and 35 mM (green outline) glucose in KRBH.  
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Figure 56. Region one gated DAF-2T fluorescence in β-cells incubated in 2.8 mM 
glucose (purple) and with ARC401 (0.05 μg/μl) (black outline) KRBH.  
 
Figure 57. Region one gated DAF-2T fluorescence in β-cells incubated in 35 mM 
glucose (green) and with ARC401 (0.05 μg/μl) (black outline) in KRBH.  
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7. Production of tumor necrosis factor alpha (TNF-α) by peripheral blood 
mononuclear cells (PMBCs) 
Peripheral blood mononuclear cells (PBMCs) were retrieved by histopaque centrigugation 
from whole blood drawn from adult, male Wistar rats. TNF-α production by PBMCs 
following 24 hour chronic incubation with 0.05 μg/μl ARC401 extract and 2ng/ml 
lipopolysaccharides (LPS) was measured in the culture media using an ELISA kit. PBMC 
viability was determined using a trypan blue exclusion viability assay. 
 
7.1. PBMC viability 
The number of viable cells per well was comparable across all treatments (figure 58). 
ARC401 was not toxic to PBMCs, nor was LPS. 
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Figure 58. Viable PBMCs per well following chronic exposure to ARC401 extract and 
LPS. Results are the mean of four replicates in one experiment + standard deviation. 
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7.2. Quantification of TNF-α produced by PBMCs 
ARC401 extract had no effect on TNF-α production by isolated rat PBMCs with or without 
LPS stimulation (figure 59). LPS significantly increased TNF-α production by isolated rat 
PBMCs. 
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Figure 59. TNF-α production in PBMCs following chronic exposure to ARC401 
extract and LPS. Results are the mean of four replicates in one experiment + standard 
deviation. * p<0.05, ** p<0.01 compared to negative control.  
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8. Summary of results 
 
8.1. Summary of in vitro results 
8.1.1. Glucose uptake and metabolism 
 
Table 1. Summary of the effect of ARC401 in C2C12, Chang and 3T3-L1 cells 
Glucose uptake Glucose oxidation Glycogen content
Insulin signalling 
gene expression
C2C12 ↑↑↑ ↑↑ - ↑INSR ↑GLUT4
Chang ↑ ↑ ↑ -
3T3-L1 ↑↑ - - -
 
↑ = p <0.05 OR fold change > 1.5; ↑↑ = p < 0.01; ↑↑↑ = p < 0.001 at maximal stimulatory concentration of 
ARC401. 
 
8.1.2. Chang cell cytotoxicity 
ARC401 reduced mitochondrial activity at the highest concentration tested (1 μg/μl). 
 
8.2. Summary of ex vivo results 
8.2.1. Glucose stimulated insulin secretion 
ARC401 increased first phase insulin secretion of β-cells in hyperglycemic conditions, 
although the increase was not significant. 
 
8.2.2. NO production 
ARC401 did not reduce NO production induced by hyperglycaemia. 
 
8.2.3. Anti-inflammatory effect in PBMCs 
ARC401 did not reduce TNF-α production of PBMCs stimulated with LPS. 
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CHAPTER 4 
DISCUSSION 
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1. Athrixia phylicoides aqueous extract (ARC401) and muscle cell glucose uptake 
and metabolism 
C2C12 myoblasts were morphologically differentiated into spindle shaped myocytes which 
then fused to form multi-nucleate, densely packed myotubules. The differentiated 
myocytes have increased levels of the insulin-sensitive GLUT4 and mimic normal 
physiological glucose uptake in muscle tissue (Cartailler, 2001).  
 
1.1. ARC401 increases glucose uptake in differentiated C2C12 myocytes acutely 
exposed to the extract 
Significantly increased glucose uptake following acute exposure to 1 μM insulin positive 
control confirmed that the differentiated C2C12 myocytes are sensitive to insulin or insulin-
like stimulation. The 1 μM metformin positive control also demonstrated significantly 
increased glucose uptake, further demonstrating sensitivity of the myocytes to glucose 
transport stimulation by a known anti-diabetic drug. Acute exposure of the C2C12 
myocytes to ARC401 extract increased glucose uptake in the C2C12 cells at all three 
concentrations tested. Maximal stimulation of glucose uptake was achieved at the 0.05 
µg/µl concentration, with the stimulatory activity lower at the low concentration (0.025 
µg/µl) and attenuated at the high concentration (0.1 µg/µl). The attenuated glucose uptake 
activity at the 0.1 µg/µl concentration could be related to saturation of or changes to the 
stimulatory pathway. Glucose uptake data in the C2C12 cells indicate that ARC401 extract 
is highly active in muscle; Van de Venter et al. (2008) described extracts with the ability to 
stimulate glucose uptake in muscle cells by more than 150%, as very active.  
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1.2. ARC401 increases glucose metabolism in differentiated C2C12 myocytes 
acutely exposed to the extract  
The increased glucose taken up by the C2C12 myocytes was actively oxidized to CO2 and 
energy (ATP and NADH). Although the glycogen content of C2C12 myocytes was not 
significantly increased by ARC401, a dose related increase in intracellular glycogen 
content was found with increasing concentrations of extract. Increasing plasma 
concentrations of insulin have been previously correlated with predominating glycogen 
synthesis (DeFronzo, 2004). At the highest concentration tested (0.1 μg/μl), ARC401 
increased glycogen storage comparable with that of insulin-stimulated storage. The 
oxidation of 14C-glucose to 14CO2 by C2C12 myocytes was significantly increased following 
acute exposure to ARC401 at 0.05 and 0.1 μg/μl. The maximal stimulatory effect of 14C-
glucose oxidation to 14CO2 at the two high doses was similar to that of insulin and 
metformin positive controls. Increase in glucose oxidation may be as a result of insulin-like 
stimulation by ARC401 of pyruvate dehydrogenase, which plays a pivotal role in glucose 
oxidation (DeFronzo, 2004). 
  
1.3. ARC401 increases insulin receptor (INSR) and glucose transporter four 
(GLUT4) expression in differentiated C2C12 myocytes acutely exposed to the 
extract  
Gene expression PCR analysis showed that ARC401 increased INSR expression 2.7 fold. 
The insulin positive control also increased INSR expression in the C2C12 myocytes 3 fold. 
Furthermore, ARC401 increased GLUT4 expression 2 fold, with insulin positive control 
increasing GLUT4 expression in the C2C12 cells 1.4 fold. These data suggest that 
ARC401 stimulated glucose uptake via INSR and GLUT4 in an insulin-mimetic manner. 
With defects in GLUT4 incorporation into the plasma membrane being characterized as 
one of the well-defined defects in glucose uptake in type II diabetes (Bryant et al., 2002; 
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Hoehn et al., 2008), increased gene expression and subsequent increased protein 
expression of GLUT4 have therapeutic implications. ARC401 stimulated increased glucose 
uptake and metabolism in C2C12 myocytes, the concurrent increase in INSR and GLUT4 
in these cells demonstrates potential insulin-mimetic properties of ARC401. However, the 
protein expression of these insulin-signalling genes needs some interrogation in order to 
determine potential alternative, non-insulin stimulatory pathway/s. Post-transcriptional 
modification of proteins (e.g. phosphorylation) also needs to be investigated in order to 
determine the total effect of ARC401 on the glucose uptake pathway. 
 
ARC401 did not show any effect on the IRS genes (one and two), or on PI3K gene 
expression. Since the proteins regulated by the IRS genes are themselves regulated by 
phosphorylation (i.e. activated upon tyrosine phosphorylation), further interrogation of the 
state of phosphorylation of these proteins is required. Although PI3K gene expression is 
not changed, its state of activity is dependent on the binding of its p85 regulatory SH2 
domain subunit to tyrosine phosphorylated IRS (Sesti, 2006). Hence the real time reverse 
transcriptase snap-shot of PI3K expression does not necessarily discriminate between 
activated PI3K bound to IRS and non-activated PI3K in the cytoplasmic pool. Chakraborty 
(2006) described the necessity for PI3K in insulin-stimulated glucose uptake, but proposed 
that an additional pathway (independent of PI3K) may exist. Chakraborty proposed insulin-
stimulated exocytosis of GLUT4 as mimicking that of exocytosis of synaptic vesicles. Thus 
soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) 
interactions may operate parallel to PI3K initiation of GLUT4 translocation. 
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2. Athrixia phylicoides aqueous extract (ARC401) and liver cell glucose uptake and 
metabolism 
The Chang liver cell strain was established from non-malignant human tissue of epithelial 
origin by R.S. Chang. Chang cells are a well established and continuously used cell line 
for in vitro glucose screening of potential drug candidates (including anti-diabetic agents) 
(Hwang et al., 2007; Van de Venter et al., 2008 and Adam et al., 2009). Chang cells were 
exposed to pyruvate-free 8 mM glucose media, which represents postprandial glucose 
concentrations. The media also contained either ARC401 extract or controls (insulin, 
metformin and water). 
 
2.1. ARC401 increases glucose uptake in Chang cells acutely exposed to the 
extract 
Sensitivity of Chang cells to stimulation of glucose uptake pathway/s was confirmed with 
significant increase in glucose uptake by both 1 μM insulin and 1 μM metformin positive 
controls. ARC401 also increased glucose uptake in the Chang cells, with a significant 
increase at the two higher concentrations (0.05 and 0.1 μg/μl). Insulin stimulated glucose 
uptake in Chang cells (although significant) was not as marked as in the C2C12 myocytes 
since splanchnic tissues (like liver) are known to be largely unaffected by insulin 
stimulation with regard to glucose uptake (DeFronzo, 2004). Similarly, the glucose uptake 
stimulated by ARC401 was more marked in the C2C12 myocytes than the Chang cells, 
further indicating insulin-mimetic properties of the extract. 
 
2.2. ARC401 increases glucose metabolism in Chang cells acutely exposed to the 
extract  
Chang cells were impartial to oxidisation or storage (as glycogen) of the increased amount 
of glucose taken up. Both oxidation of 14C-glucose to 14CO2 and glycogen storage was 
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significantly increased by ARC401 in the Chang cells. Chang cell oxidation of 14C-glucose 
to 14CO2 increased in a dose-dependent manner as concentrations of ARC401 increased. 
Significant increases in oxidation were observed at the two higher concentrations (0.05 
and 0.1 μg/μl); interestingly, these are the same two doses that stimulated significant 
glucose uptake from the media in these cells. The glucose oxidation of Chang cells acutely 
exposed to the highest concentration of ARC401 (0.1 μg/μl) was higher than that of both 
insulin and metformin controls. Glycogen storage was significantly increased at all three 
concentrations of ARC401 tested. The glycogen content of Chang cells acutely exposed to 
ARC401 (at all three concentrations) was comparable with that of Chang cells acutely 
exposed to insulin and metformin positive controls. Both basal and insulin-stimulated 
glycogen synthesis ability is diminished in T2D (DeFronzo, 2004), therefore therapeutics 
that enhance glycogen storage in liver can aid in ameliorating the adverse effects 
associated with dysfunctional glucose metabolism. The ability of ARC401 to stimulate 
glycogen storage in Chang cells represents the ability of the extract to induce insulin-like 
actions in these cells, since insulin is known to increase glycogen synthase activity and 
subsequent glycogen storage (Cohen, 1999). The ability of Chang cells to respond to 
insulin-like stimulation of ARC401 in terms of glycogen storage initiates the consideration 
that, like insulin, ARC401 possesses the ability to decrease the hyperglycemic onslaught 
attributed to HGP. Overall, ARC401 enhanced metabolism of the increased glucose taken 
up by Chang cells. 
 
2.3. ARC401 has no detectable effect on insulin-signalling gene expression in 
Chang cells acutely exposed to the extract  
Gene expression analysis showed that ARC401 had no effect on insulin-signalling gene 
expression in Chang cells. In order to further elucidate the effect of ARC401 on the insulin 
signalling pathway in Chang cells, future work should include the relative expression of 
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GLUT1 and GLUT2, as well as the phosphorylated isoforms of IRS1/2. It would also be 
interesting to investigate the relative expression of the glucokinase gene in liver and liver-
like cells since glucokinase plays an important role in glucose oxidation in this tissue type. 
 
2.4. ARC401 has no cytotoxic effects on Chang cells exposed to the extract  
The MTT assay is a rigorous and well described technique used to determine potential 
cytotoxic effects in vitro (Mossman, 1983). Since MTT solution (tetrazolium bromide) is 
reduced in active mitochondria by mitochondrial dehydrogenase to purple formazan 
crystals, quantification of formazan formation using this assay provides insight into the 
mitochondrial activity of Chang cells. ARC401 did not inhibit mitochondrial activity nor were 
cytotoxic effects observed in Chang cells exposed to the extract for 24 hours at increasing 
concentrations (0.0125 - 1 μg/μl). At all concentrations tested optical densities at 570 nm 
were above 60% of that of the vehicle control. At the highest concentration, ARC401 
induced reduced mitochondrial activity in the Chang cells. This may be as a result of an 
antagonistic concentration effect (Peng et al., 2005). 
 
3. Athrixia phylicoides aqueous extract (ARC401) and adipocyte glucose uptake 
and metabolism 
3T3-L1 pre-adipocytes were morphologically differentiated from fibroblastic, progenitor 
mesenchymal cells to rounded, fully functional, fat-producing adipocytes. Insulin, 
dexamethasone and isobutylmethylxanthine were added to the culture media in order to 
induce this differentiation since these agents are known to promote adipocyte 
differentiation by activating PI3K and protein kinase B (PKB, aka Akt) (Jain and Yadav, 
2009). These agents also facilitate the expression of peroxisome proliferator-activated 
receptor gamma (PPARγ) and cytidine-cytidine-adenosine-adenosine-thymidine-enhancer-
binding protein alpha, which are considered master regulators of adipogenisis (Farmer, 
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2006). The differentiated 3T3-L1 adipocytes and were exposed to pyruvate-free 8 mM 
glucose media, which physiologically represents postprandial glucose concentrations. The 
media also contained either ARC401 extract or controls (insulin, metformin and water). 
 
3.1. ARC401 increases glucose uptake in differentiated 3T3-L1 adipoycytes 
acutely exposed to the extract 
Stimulated glucose uptake via GLUT1 and GLUT4 has been demonstrated in 3T3-L1 
adipocytes (Kotani et al., 1998 and Bosch et al., 2004). The differentiated adipocytes used 
in this study demonstrated significantly increased glucose uptake when stimulated with 
insulin positive control and thus mimic the physiological process of glucose uptake in 
normal adipose tissue.  Rat adipocytes, in vitro, demonstrate the ability to increase 
translocation of GLUT4 to the plasma membrane in response to metformin, thus facilitating 
increased glucose uptake (Matthaei et al., 1991 and Kozka and Holman, 1993). In this 
study metformin significantly increased glucose uptake in the 3T3-L1 adipocytes following 
acute exposure. Acute exposure of the 3T3-L1 adipocytes to ARC401 extract increased 
stimulation of glucose uptake. Maximal stimulation of glucose uptake was achieved at the 
0.025 and 0.05 µg/µl concentrations. Attenuation of the stimulatory glucose uptake effect 
of ARC401 was observed at the high concentration (0.1 µg/µl), albeit that the percentage 
of glucose taken up was still higher than that of the vehicle control. The attenuated glucose 
uptake activity at the 0.1 µg/µl concentration could be related to saturation of or changes 
to the stimulatory pathway.  
 
3.2. ARC401 has no measurable effect on glucose metabolism in differentiated 
3T3-L1 adipoycytes acutely exposed to the extract 
ARC401 did not increase 14C-glucose oxidation to 14CO2 in the 3T3-L1 adipocytes; albeit, 
neither did insulin and metformin positive controls. A trend toward decreasing 14C-glucose 
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oxidation with increasing ARC401 concentrations was seen, which may infer that ARC401 
reduces glucose oxidation, and potentially favours the storage of increased glucose taken 
up as lipid/fat. Further experimental assay/s should be performed in order to determine the 
effect of ARC401 on adipogenesis in the 3T3-L1 adipocytes. The glycogen content of 3T3-
L1 adipocytes was not detectable by the assay used in this study – values obtained were 
less than the minimum value in the standard curve (i.e. 0.04 μg/well) since adipocytes 
store less glycogen compared to myo- and hepato- cytes. Cells used in the glycogen 
content assays were lysed and homogenized to release the intracellular glycogen (see 
section 2.6.2 in chapter two). This method of glycogen extraction also releases cellular 
lipid, which may in fact compromise the glycogen determination assay by non-specifically 
interacting with the BioVision glycogen content kit components. 
 
3.3. ARC401 effect on insulin-signalling gene expression in differentiated 3T3-L1 
adipoycytes acutely exposed to the extract 
Insulin-signalling gene expression in differentiated 3T3-L1 adipoycytes acutely exposed to 
ARC401 was inconclusive as the probes purchased to perform the analysis failed to bind 
to the cDNA synthesized from these cells. As with the undetectable glycogen content seen 
in these adipocytes, failure of primers binding to their target sequences on the cDNA could 
possibly be as a result of lipid contamination interactions. In order to further elucidate the 
effect of ARC401 on the insulin signalling pathway in 3T3-L1 adipocytes, future work 
should include analysis of insulin-signalling protein expression as well as gene expression 
analysis using new probes or alternatively, designing new primers. 
 
4. Glucose stimulated insulin response and antioxidant effect of Athrixia 
phylicoides aqueous extract (ARC401) in pancreatic β-cells 
Pancreatic β-cells obtained from adult, male Wistar rats were pre-exposed to ARC401 
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extract (0.05 μg/μl) for 24 hours and then cultured in increasing concentrations of glucose. 
The 2.8 mM concentration represented normal physiological glucose concentrations in 
vivo. The 17 and 35 mM glucose concentrations represented stimulated and hyper-
stimulated glucose concentrations. Hyperglycaemia is a known stimulus of β-cell oxidative 
stress, either due to the higher demand for insulin synthesis and secretion, or as a result of 
glucotoxicity (Bonora, 2008). Only one experimental repeat was performed in these 
assays, however, the important process of establishing a viable protocol was achieved. 
 
4.1. The effect of ARC401 on insulin secretion in response to glucose stimulation 
ARC401 pre-exposed pancreatic islets showed slightly reduced first and second phase 
insulin response at low glucose (2.8 mM) concentrations. At higher glucose concentrations 
(both 17 mM and 35 mM glucose), ARC401 increased the first phase insulin response and 
decreased second phase insulin without neural modulation that occurs in the intact 
pancreas. At hyperstimulatory glucose concentrations (e.g. 35 mM), an increase in first 
phase insulin response would release most, if not all, insulin granules in the cytoplasm of 
the islets. The reduction in second phase insulin secretion (i.e. secretion of newly 
synthesized insulin) would be as a result of increased first phase insulin secretion. 
Interestingly, high glucose stimulation (at both 17 mM and 35 mM glucose) did not induce 
a significant increase in first or second phase insulin secretion. This assay was performed 
with only one repeat due to limited resource and time; however further repetition using a 
larger number of islets will provide significant insights into β-cell glucose response and the 
effect of ARC401 in this response. Several studies have reported that exposure of 
pancreatic islets to gluco- (or lipo-) toxic conditions activates inducible nitric oxide 
synthase with a concomitant reduction in insulin response to glucose stimulation 
(Henningsson et al., 2002; Salehi et al., 2003 and Jimenez-Felstrom et al., 2005). This 
correlates with the glucose stimulated insulin response data in this study, where high 
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glucose (17 mM and 35 mM) failed to significantly increase insulin secretion (and 
synthesis) in isolated pancreatic islets of Langerhans. Salehi et al. (2003) proposed that 
NO derived from neuronal constitutive nitric oxide synthase (ncNOS) might serve as a 
negative feedback inhibitor of acute glucose stimulated insulin release. Future studies 
should include not only quantification of NO produced by pancreatic β-cells, but also via 
which synthesis enzyme it was derived (i.e. be it from ncNOS, or endothelial NOS, or 
inducible NOS, etc.). 
 
4.2. The antioxidant effect of ARC401 in pancreatic β-cells 
β-cells used for this component of the study were only exposed to two glucose 
concentrations (i.e. 2.8 and 35 mM glucose). A control sample of β-cells were gated based 
on their higher granularity and/or larger size. Cellular debris, miscellaneous endothelial 
cells and other islet cells, such as α-cells and δ-cells were subsequently excluded from the 
analysis by this gate. The decrease in DAF-2T fluorescence indicates a decrease in NO 
production by β-cells pre-exposed to ARC401 at 2.8 mM glucose. This decrease in NO 
correlates with the slightly reduced insulin secretion by β-cells pre-exposed to ARC401 at 
2.8 mM glucose. The correlation is due to NO being a key regulator of insulin secretion in 
β-cells (Campbell et al., 2007). Although NO is an important part of insulin secretion, at 
increased levels it is known to provoke increased β-cell oxidative stress (Campbell et al., 
2007). Hyperglycaemic induction of β-cell oxidative stress and a reduced amount of anti-
oxidants (e.g. glutathione) in β-cells may impair β-cell function and thus insulin secretion 
(Campbell et al., 2007). The results in this study correlate with hyperglycaemic (35 mM 
glucose) induction of increased NO production by β-cells, as well as failure of the β-cells to 
respond to hyperglycaemia. ARC401 was unable to reduce the amount of NO produced at 
35 mM glucose, which indicates that ARC401 does not have a significant effect on NO 
production in isolated rat pancreatic β-cells.  
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5. Anti-inflammatory effect of Athrixia phylicoides aqueous extract (ARC401) in 
PBMCs 
PBMCs have been commonly used to demonstrate potential anti-inflammatory effects of 
agents. Using purified PBMCs as opposed to whole blood culture offers the advantage of 
not having interference from other blood cells that may act with the test compound 
differently and compromise the inflammatory effect in PBMCs (Crouvezier at al., 2001). 
PBMCs have also been shown to ellicit a potent inflammatory response when stimulated 
with LPS. In this study, LPS isolated from E. coli were used. These LPS significantly 
increased TNF-α production by PBMCs isolated from adult, male Wistar rat whole blood. 
ARC401 failed to decrease TNF-α in the isolated PBMCs, showing no measurable effect 
on induced inflammation. Although ARC401 failed to decrease TNF-α production by 
PBMCs stimulated by LPS, ARC401 may yet have an anti-inflammatory effect. The anti-
inflammatory effect of ARC401 may be less pronounced and hence future studies should 
consider the use of a less potent inflammatory stimulation (e.g. the use of cytokine 
stimulation). 
 
The study by Crouvezier et al. in 2001 demonstrated the ability of selected tea polyphenols 
to decrease the production of IL-1β by whole blood and purified PBMC cultures. A 
reduction in TNF-α was not seen in this study. Similarly, ARC401 may also ellicit an anti-
inflammatory effect in PBMC‟s via the reduction of the pro-inflammatory cytokine IL-1β by 
a pathway independent of NFκB.  
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CHAPTER 5 
CONCLUSIONS 
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Limitations of the study and prospective research 
Despite this study showing that the aqueous extract of A. phylicoides increases glucose 
uptake and metabolism in vitro, the in vivo effects still need to be established. Absorption 
and metabolism of the active agents in the plant needs to be investigated. Isolating these 
active agents by extract fractionation will allow for synthetic mass production of an anti-
diabetic drug (Haslam, 1996). Future work should involve severe hyperglycaemic 
conditions (e.g. above 17 mM glucose in an streptozotocin-induced diabetic rat model) 
since it is this severe hyperglycaemia that results in the numerous diabetic complications 
and also further exacerbates the deteriorating diabetic state (Johansen et al., 2005, and 
Houstis et al., 2006). In order to further elucidate the insulin signalling pathway, the effect 
of the extract on phosphorylated isoforms of key insulin signalling molecules should be 
investigated since these are the active forms. Since A. phylicoides extract may work via a 
pathway similar but not exclusive to insulin signalling, the effect of the extract on enzymes 
involved in rate limiting reactions of glucose metabolism (e.g. hexokinase, glycogen 
synthase) should also be investigated. New probes or primers that are specific for our 3T3-
L1 cell line need to be designed and/or purchased, since the current mouse probes failed 
to bind to targeted sequences in the 3T3-L1 adipocytes. 
 
The largest limitation of the ex vivo component of this study was the limited number of 
animals available for pancreatic islet isolations. Due to their relative size compared to 
primates or humans, adult male Wistar rats yielded an average of 200 pancreatic islets per 
animal; in future larger number of animals should be used. Alternatively in vitro β-cell lines 
(e.g. INS1 and MIN6 cell lines) can be used to compliment the ex vivo data generated. 
Along with repeated experimental data on insulin secretion and NO production, the effect 
of A. phylicoides extract on the total anti-oxidant status of pancreatic β-cells should be fully 
elucidated; i.e. total ROS versus total anti-oxidants (e.g. catalase, super oxide dismutase, 
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glutathione). The insulin-sparing effect of the extract should be considered in future work; 
i.e. the ability of the extract to sensitise tissues such that less insulin is required to 
maintain normoglycemia, thus reducing the stress on β-cells. 
 
Included in future studies should also be the effect of A. phylicoides aqueous extract on 
the production of IL-6 since this pro-inflammatory cytokine is also regulated by the same 
NFκB as TNF-α and IL-1β. In order to determine the complete effect of ARC401 on 
inflammation, the effect of the extract on anti-inflammatory cytokines (e.g. interleukin 10) 
should be investigated. The extract may also ellicit anti-inflammatory effects attributed to 
plant polyphenols by suppressing the infiltration of leukocytes into target organs as 
demonstrated by Katiyar and colleagues in 1999. Future studies should also consider the 
use of less potent inflammatory stimulation (e.g. the use of cytokine stimulation). 
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Concluding remarks 
With changes in the socio-economic climate and a new trend in merging Western lifestyle 
with traditional practices, new interest has been shown in herbal/natural remedies (van 
Wyk and Gericke, 2000, and Rampedi and Olivier, 2005). Scientific verification of potential 
health benefits of plant therapeutics is necessary for universal acceptance. 
 
This study demonstrates that Athrixia phylicoides aqueous extract not only increases the 
amount of glucose taken up in peripheral tissues (i.e. muscle and adipose), but also shows 
enhanced glucose uptake in liver in vitro. The extract also increased the in vitro ability of 
muscle and liver cells to metabolise glucose in an insulin-mimetic manner. Athrixia 
phylicoides extract had no measurable effect ex vivo on anti-oxidative and anti-
inflammatory statuses of pancreatic β-cells and peripheral mononuclear cells respectively. 
First phase insulin secretion of pancreatic β-cells was enhanced by the extract. 
 
The effects of Athrixia phylicoides aqueous extract on in vitro glucose metabolism suggest 
that this extract could potentially be beneficial to type II diabetics as an adjunct therapy. 
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APPENDIX I – Reagent Components 
 
1. Dulbecco’s modified Eagle’s medium (DMEM) (Cat No.: 12-741F) 
 
Inorganic salts      mg/L 
CaCl2 (anhyd.)      200 
Fe(NO3)3•9H2O      0.10 
KCl        400 
MgSO4•7H2O      200 
NaCl        6 400 
NaHCO3       3 700 
NaH2PO4•H2O      125 
 
Amino acids      mg/L 
L-Arginine•HCl      84 
L-Cysteine       48 
L-Glutamine       584 
Glycine       30 
L-Histidine•HCl•H2O     42 
L-Isoleucine       104.8 
L-Leucine       104.8 
L-Lysine•HCl       146.2 
L-Methionine       30 
L-Phenylalanine      66 
L-Serine       42 
L-Threonine       95.2 
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Amino acids      mg/L 
L-Tryptophan      16 
L-Tyrosine       72 
L-Valine       93.6 
 
Vitamins       mg/L 
D-Ca Pantothenate      4 
Choline chloride      4 
Folic acid       4 
i-Inositol       7 
Nictotinamide      4 
Pyridoxine•HCl      4 
Riboflavin       0.4 
Thiamine•HCl      4 
 
Other components      mg/L 
Glucose       4 500 
Phenol red       15 
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2. Eagle’s modified essential medium (EMEM) (Cat No.: 12-662F) 
 
Inorganic salts      mg/L 
CaCl2•2H2O       265 
KCl        400 
MgSO4•7H2O      200 
NaCl        6 800 
NaHCO3       2 200 
NaH2PO4•H2O      140 
 
Amino acids      mg/L 
L-Alanine       8.9 
L-Arginine•HCl      126.4 
L-Asparagine      13.21 
L-Aspartic acid      13.3 
L-Cysteine       24 
L-Glutamic acid      14.7 
Glycine       7.5 
L-Histidine•HCl•H2O     42 
L-Isoleucine       52.4 
L-Leucine       52.4 
L-Lysine•HCl       73 
L-Methionine       15 
L-Phenylalanine      33 
L-Proline       11.5 
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Amino acids      mg/L 
L-Serine       10.5 
L-Threonine       47.6 
L-Tryptophan      10.2 
L-Tyrosine       36.2 
L-Valine       46.8 
 
Vitamins       mg/L 
D-Ca Pantothenate      1 
Choline chloride      1 
Folic acid       1 
i-Inositol       2 
Nictotinamide      1 
Pyridoxal•HCl      1 
Riboflavin       0.1 
Thiamine•HCl      1 
 
Other components      mg/L 
Glucose       1 000 
Phenol red•Na      10 
Sodium pyruvate      110 
 
144 | 
 
 
3. Dulbecco’s modified Eagle’s medium base (Cat No.: D5030) 
 
Inorganic salts      mg/L 
CaCl2 (anhydrous)      200 
Fe(NO3)3•9H2O      0.10 
KCl        400 
MgSO4 (anhydrous)      97.67 
NaCl        6 400 
NaH2PO4•H2O      109 
 
Amino acids      mg/L 
L-Arginine•HCl      84 
L-Cysteine•2HCl       62.6 
Glycine        30 
L-Histidine•HCl• H2O      42 
L-Isoleucine        105 
L-Leucine        105 
L-Lysine•HCl       146 
L-Methionine       30 
L-Phenylalanine       66 
L-Serine        42 
L-Threonine        95 
L-Tryptophan      16 
L-Tyrosine•2Na•2 H2O      103.8 
L-Valine        94 
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Vitamins       mg/L 
Choline Chloride       4 
Folic Acid        4 
Myo-Inositol        7.2 
Niacinamide        4 
D-Pantothenic Acid Hemicalcium     4 
Pyridoxal•HCl       4 
Riboflavin        0.4 
Thiamine•HCl       4 
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4. RPMI 1640 Medium (Cat No.: 12-702F) 
 
Inorganic salts      mg/L 
Ca(NO3)2•4H2O      100 
KCl        400 
MgSO4•7H2O      100 
NaCl        6 000 
NaHCO3       2 000 
Na2HPO4•7H2O      1 512 
 
Amino acids      mg/L 
L-Arginine       200 
L-Asparagine•H2O      50 
L-Aspartic acid      20 
L-Cysteine       50 
L-Glutamic acid      20 
L-Alanyl-L-Glutamine (UltraGlutamine 1)   446 
Glycine       10 
L-Histidine       15 
Hydroxy L•Proline      20 
L-Isoleucine       50 
L-Leucine       50 
L-Lysine•HCl       40 
L-Methionine       15 
L-Phenylalanine      15 
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Amino acids      mg/L 
L-Proline       20 
L-Serine       30 
L-Threonine       20 
L-Tryptophan      5 
L-Tyrosine       20 
L-Valine       20 
 
Vitamins       mg/L 
p-Aminobenzoix Acid     1 
d-Biotin       0.2 
D-Ca Pantothenate      0.25 
Choline chloride      3 
Folic acid       1 
i-Inositol       35 
Nictotinamide      1 
Pyridoxine•HCl      1 
Riboflavin       0.2 
Thiamine•HCl      1 
Vitamin B12       0.005 
 
Other components      mg/L 
Glucose       2 000 
Glutathione (reduced)     1 
Phenol red•Na      5 
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5. Dulbecco’s phosphate buffered saline (PBS) (Cat No.: 17-513) 
 
Inorganic salts      mg/L 
CaCl2•H2O       130 
KCl        200 
KH2PO4       200 
MgCl2•6H2O       100 
NaCl        8 000 
Na2HPO4•7H2O      2 160 
 
1. Hanks Balanced Salt Solution (Cat No.: 14025) 
 
Inorganic salts      mg/L 
CaCl2•H2O       186 
KCl        400 
KH2PO4       60 
MgSO4•7H2O      200 
NaCl        8 000 
NaHCO3       350 
Na2HPO4•7H2O      90 
 
Other components      mg/L 
Glucose       1 000 
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6. Krebs-Ringer bicarbonate HEPES buffer 
Component       mmol/L 
NaCl        115 
NaHCO3       24 
KCl        5 
MgCl2        1 
CaCl2        2.5 
2% BSA 
10 mM HEPES Buffer 
 
7. Sorennson’s Buffer pH 10.5  
0.751 g glycine (0.1M) + 0.584 g NaCl (0.1M) (in 100 ml cell culture tested water). 
4 g NaOH (1M) in 100 ml cell culture tested water (to equilibrate buffer to pH 10.5). 
 
 
9. 0.3 M NaOH + 1% SDS 
12 g NaOH (0.3M) + 100 ml 10% SDS solution (in 1 L cell culture tested water). 
 
9. Trypsin (Cat No.: 17-161F) 
0.5 g/L irradiated porcine trypsin + 0.2 g/L Versene® (EDTA) 
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APPENDIX II – Supplementary tables 
 
Table 2. Abbreviated cell sample labels for C2C12 (a), Chang (b) and 3T3-L1 (c) cells 
 
a. 
Insulin (1 .0 μM) A1
Metformin (1 .0 μM) A2
Vehicle (water) A3
ARC401 (0.05 μg/μl) A5
Insulin (1 .0 μM) B1
Metformin (1 .0 μM) B2
Vehicle (water) B3
ARC401 (0.05 μg/μl) B5
Insulin (1 .0 μM) C1
Metformin (1 .0 μM) C2
Vehicle (water) C3
ARC401 (0.05 μg/μl) C5
Sample Abbreviated Label
 
 
b. 
Insulin (1 .0 μM) D1
Metformin (1 .0 μM) D2
Vehicle (water) D3
ARC401 (0.05 μg/μl) D5
Insulin (1 .0 μM) E1
Metformin (1 .0 μM) E2
Vehicle (water) E3
ARC401 (0.05 μg/μl) E5
Insulin (1 .0 μM) F1
Metformin (1 .0 μM) F2
Vehicle (water) F3
ARC401 (0.05 μg/μl) F5
Sample Abbreviated Label
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c. 
Insulin (1 .0 μM) G1
Metformin (1 .0 μM) G2
Vehicle (water) G3
ARC401 (0.05 μg/μl) G5
Insulin (1 .0 μM) H1
Metformin (1 .0 μM) H2
Vehicle (water) H3
ARC401 (0.05 μg/μl) H5
Insulin (1 .0 μM) I1
Metformin (1 .0 μM) I2
Vehicle (water) I3
ARC401 (0.05 μg/μl) I5
Sample Abbreviated Label
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Table 3. Nanodrop quantification of RNA (ng/μl and μg/ml) and 20 μg RNA dilution in 
RNase-free water (μl) for C2C12 cells (a) Chang cells (b) and 3T3-L1 cells (c) 
 
a. 
A1 619.02 32.31 9.69
A2 226.82 42.00 0.00
A3 222.90 42.00 0.00
A5 758.97 26.35 15.65
B1 834.35 23.97 18.03
B2 743.57 26.90 15.10
B3 559.58 35.74 6.26
B5 856.93 23.34 18.66
C1 129.50 42.00 0.00
C2 241.41 42.00 0.00
C3 380.45 42.00 0.00
C5 19.18 42.00 0.00
Sample ng/μl 20 µg RNA (μl) Water (μl)
 
 
b. 
D1 1132.79 17.66 24.34
D2 1274.97 15.69 26.31
D3 279.76 42.00 0.00
D5 1318.56 15.17 26.83
E1 533.78 37.47 4.53
E2 1168.22 17.12 24.88
E3 1237.71 16.16 25.84
E5 513.26 38.97 3.03
F1 2885.40 6.93 35.07
F2 123.15 42.00 0.00
F3 2230.42 8.97 33.03
F5 1776.42 11.26 30.74
Sample ng/μl 20 µg RNA (μl) Water (μl)
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c. 
G1 322.03 42.00 0.00
G2 757.10 26.42 15.58
G3 686.17 29.15 12.85
G5 827.38 24.17 17.83
H1 294.55 42.00 0.00
H2 195.95 42.00 0.00
H3 267.88 42.00 0.00
H5 121.00 42.00 0.00
I1 198.76 42.00 0.00
I2 7.44 42.00 0.00
I3 292.95 42.00 0.00
I5 312.68 42.00 0.00
Sample ng/μl 20 µg RNA (μl) Water (μl)
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Table 4. Nanodrop quantification of RNA (ng/μl and μg/ml) and 1 μg RNA dilution in 
RNase-free water (μl) for C2C12 cells (a) Chang cells (b), 3T3-L1 cells (c) and positive 
and negative controls (d) 
 
a.  
A1 338.67 2.95 7.05
A2 160.97 6.21 3.79
A3 158.54 6.31 3.69
A5 333.96 2.99 7.01
B1 332.53 3.01 6.99
B2 329.79 3.03 6.97
B3 330.26 3.03 6.97
B5 333.18 3.00 7.00
C1 63.50 10.00 0.00
C2 173.35 5.77 4.23
C3 264.18 3.79 6.21
C5 18.80 10.00 0.00
Sample ng/μl 1 µg RNA (μl) Water (μl)
 
 
b. 
D1 343.95 2.91 7.09
D2 330.17 3.03 6.97
D3 194.80 5.13 4.87
D5 317.49 3.15 6.85
E1 370.41 2.70 7.30
E2 342.51 2.92 7.08
E3 344.22 2.91 7.09
E5 325.68 3.07 6.93
F1 239.29 4.18 5.82
F2
F3 303.77 3.29 6.71
F5 397.94 2.51 7.49
Insufficent sample - removed from experiment
ng/μl 20 µg RNA (μl) Water (μl)Sample 
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c. 
G1 230.92 4.33 5.67
G2 327.70 3.05 6.95
G3 340.46 2.94 7.06
G5 324.21 3.08 6.92
H1 212.80 4.70 5.30
H2 143.20 6.98 3.02
H3 204.68 4.89 5.11
H5 83.14 10.00 0.00
I1 148.20 6.75 3.25
I2 9.74 10.00 0.00
I3 186.10 5.37 4.63
I5 237.44 4.21 5.79
Sample ng/μl 20 µg RNA (μl) Water (μl)
 
 
d. 
0.00 1.00 9.00
0.00 1.00 9.00
0.00 0.00 10.00
Water (μl)Sample 
Amb Mouse +ve control
Amb Human +ve control
Water -ve control
ng/μl 1 µg RNA (μl)
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Table 5. Sample key for cDNA PCR test plate 
 
A1 1 E3 21
A2 2 E5 22
A3 3 F1 23
A5 4 F3 24
B1 5 F5 25
B2 6 G1 26
B3 7 G2 27
B5 8 G3 28
C1 9 G5 29
C2 10 H1 30
C3 11 H2 31
C5 12 H3 32
D1 13 H5 33
D2 14 I1 34
D3 15 I2 35
D5 16 I3 36
E1 17 I5 37
E2 18 Amb Mouse 38
Water 20 Amb Human 39
Abbreviated Label Abbreviated LabelKey Key
 
 
 
